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Abstract 
Choline is the precursor of acetylcholine, the endogenous neurotransmitter responsible for activation 
of muscarinic and nicotinic acetylcholine receptors. At the same time, choline is also the metabolite of 
acetylcholine following synaptic degradation by acetylcholine esterase. It is thus not surprising that 
choline is an important biomolecule and, in fact, an essential nutrient because its biosynthesis is 
insufficient to meet the demands of the body. Choline has also been found to directly activate some 
nicotinic acetylcholine receptors, which suggests that it may play a role in neurotransmission beyond 
being a precursor/metabolite. The present thesis evaluates pharmacological effects of choline on α4β2 
neuronal nicotinic acetylcholine receptors (nAChRs). 
 
Using electrophysiological techniques, the study investigates effects of choline on currently known 
α4β2 nAChRs stochiometries ― (α4)3(β2)2 and (α4)2(β2)3. Choline was found to activate (α4)3(β2)2 
nAChRs with EC50 of 0.4mM and a maximal efficacy of 4%. In contrast, it did not produce any 
response on (α4)2(β2)3, suggesting that an α4α4 interface is required in order to observe choline 
effect. When co-applied with ACh we revealed that low concentrations of choline potentiated currents 
induced by 1 µM and 10 µM ACh, but these effects were inhibited by 1mM choline or higher. In 
addition, the co-application of choline with 100 µM ACh showed inhibition with an IC50 value of 
26mM but no potentiation was observed. Preincubation of choline on (α4)3(β2)2 nAChRs 
demonstrated that ACh responses on these receptors were decreased up to 60% of their maximum 
efficacy. To further explore the effects of choline we tested the compound on mutant receptors 
engineered to only have α4α4 or α4β2-like binding sites. These engineered receptors are triple 
mutation (3M) induced on complementary interface of either α4 or β2 native subunits and are denoted 
(4)3(23M)2 or (43M)3(2)2 respectively. The (4)3(23M)2 mutant receptor bears one native α4α4 
site and two α4α4-like sites whereas (43M)3(2)2 mutant has two native α4β2 sites and one α4β2-like 
site. On these mutant constructs, choline activated the (4)3(23M)2 receptors with EC50 of 0.3mM 
and a maximum response of four percent as compared to 1mM ACh efficacy. In contrast, choline had 
no effect on (43M)3(2)2 nAChRs, highlighting the importance of the α4α4 site for choline mediated 
response. 
 
Overall our results show that at least one α4α4 binding site is required to notice choline activity on 
α4β2 nAChRs. Choline also can modulate ACh-mediated activation of nAChRs. Low concentrations 
of choline enhance ACh evoked response, but this response is inhibited by high concentrations of 
choline. This study definitely suggests that choline may contribute to balance ACh-mediated 
signalling of α4β2 nAChRs. 
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Chapter 1 
Introduction 
 
This thesis reports findings from an investigation of Choline effects on α4β2 neuronal 
nicotinic receptors. This chapter begins by locating the study’s focus in relation to relevant 
previous research and existing knowledge of the cholinergic system, with particular attention 
to the neuronal nicotinic acetylcholine receptors. This is followed by a statement of the 
study’s aim and objectives. 
1.1 The Cholinergic System  
 
In the central nervous system (CNS), the neurons that contain choline acetyltransferase 
(ChAT) enzyme and use acetylcholine (ACh) (Figure 1) as the endogenous neurotransmitter 
are called cholinergic neurons [1]. The cholinergic system is composed of two main classes 
of receptors―muscarinic and nicotinic receptors―so-called because of their high affinity 
with the natural alkaloids muscarine and nicotine, respectively [2]. Muscarine receptors are 
metabotropic receptors, which act by coupling to G proteins and which mediate 
neurotransmission slowly. In contrast, nicotinic receptors are ionotropic receptors belonging 
to the cys-loop ligand-gated ion channel superfamily. Ionotropic receptors mediate rapid 
response in neurotransmission since, in contrast to metabotropic receptors, they do not need 
G proteins as second messengers. 
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Figure 1. Structure of acetylcholine   
 
The significance of nicotinic receptors in modulating biological function stems from their 
ability to translate the binding of ACh to receptor motion that will select and allow ion flow 
through the channel and induce a cellular response [2, 3]. Since its discovery in 1914, ACh 
has been recognised as an endogenous signaling compound which is synthesised in the 
cytoplasm of the nerve terminal from choline and acetyl-CoA through the action of ChAT. 
Specifically, choline has a dual origin [3]. One of these is as an essential nutrient taken from 
a diet rich in choline or related compounds. Another source consists of denovo biosynthesis 
from phosphatidylcholine, which represents 95% of the total choline in mammalian tissue. 
Once synthesised, ACh is stored in synaptic vesicles until a nerve impulse reaches the 
presynaptic terminal, resulting in the release of ACh in the synaptic cleft to transfer the 
message to the postsynaptic terminal. The action is rapidly terminated by the 
Acetylcholinesterase to allow repolarisation. ACh is then metabolised into choline and 
acetate (Figure 2). 
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Figure 2. ACh synthesis and metabolism  
Choline and Acetyl-CoA reaction is catalysed by ChAT. The synthesised ACh is taken by vesicular ACh 
transporter (VAChT) and stored in synaptic vesicles. ACh release is initiated by an action potential on 
presynaptic neuron that opens a voltage-gated calcium channel and Ca
2+
 influx stimulates the release of ACh 
from presynaptic vesicles into the synaptic cleft. The released ACh activates the receptors on postsynaptic 
terminal nAChR or mAChR and is rapidly hydrolysed by the enzyme acetylcholinesterase (AChE) into Choline 
and acetate. Choline is then taken up by the high-affinity choline transporter (CHT)[4]. 
 
The nicotinic receptors mediate synaptic transmission at both the neuromuscular junction and 
the neuronal synapse. The muscle and neuronal nicotinic receptors (nAChRs) have been 
further subdivided into up to 17 known nAChRs subunit genes in the human genome [5]. The 
muscle type receptors include genes encoding for α1, β1, γ, δ, and ε subunits whereas 
neuronal nicotinic receptors consist of those encoding for α2 to α10 and β2 to β4 subunits. 
From these subunits, a functional receptor is made of five assembled subunits, which results 
in many possible subunit combinations and stochiometries (Table 1) thus explaining the 
diverse physiological function of nicotinic receptors. 
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Table 1 nAChRs Subtypes, Subunits and their Possible Combination  
Adapted from Millar, 2003 [5]  
Receptor subtype Subunits Subunit combinations 
Muscle type α1, β1,δ, ε, γ α1, β1, γ, δ 
  
 
α1, β1, ε, δ 
Neuronal (αBtxa-insensitive) α2-α6, β2-β4 α2β2 
  
 
α2β4 
  
 
α3β2 
  
 
α3β4 
  
 
α4β2 
  
 
α4β4 
  
 
α6β2 
  
 
α6β4 
  
 
α2α5β2 
  
 
α3α5β2 
  
 
α3α5β4 
  
 
α3α6β2 
  
 
α3α6β4 
  
 
α3β3β4 
  
 
α4α5β2 
  
 
α5α6β2 
  
 
α6β3β4 
  
 
α3α5β2β4 
  
 
α3α6β3β4 
  
 
α4α5α6β2 
  
 
α4β2β3β4 
  
 
  
Neuronal (αBtx-sensitive) α7, α8 α7 
  
 
α8 
  
 
α7β2 
  
 
α7β3 
  
 
α5α7β2 
  
 
α5α7β4 
  
 
  
Sensory epithelia α9, α10 α9 
    α9α10 
 
 
 
 
                                                          
a
 αBtx: αBangarotoxin (a snake toxin used to classify the nAChRs) 
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1.2 Neuronal Nicotinic Acetylcholine Receptors 
 
The neuronal nicotinic acetylcholine receptors (nAChRs) belong to an important subclass of 
cholinergic receptors in the CNS, where they mediate the rapid responses of ACh. nAChRs 
mediate excitatory responses and also regulate the release of a number of other 
neurotransmitters including glutamate, dopamine and noradrenaline, which are important 
neurotransmitters in memory formation and consolidation [6].  
The nAChRs consist of various α and β subunits which make up the pentameric receptor 
(Table 1). The activation of nAChRs by the binding of ACh results in an influx of Na
+
 into 
the cell and an efflux of K
+
, leading to a depolarisation of the postsynaptic neuron and the 
initiation of a new action potential [7]. Continued application of ACh on the nAChRs leads to 
the receptor’s desensitisation. This mechanism is believed to be a result of phosphorylation 
by either cAMP-dependent protein kinase A (PKA) or protein kinase C (PKC). 
nAChRs are expressed widely in the CNS. They are mainly present at presynaptic neurons, 
where they mediate neurotransmitter release, but they also modulate postsynaptic effects on 
dendrites and are implicated in cell excitability and neuronal integration [8].  These processes 
play important physiological roles including arousal, anxiety, and varied cognitive functions. 
It is therefore not surprising that nAChR dysfunction or imbalance can lead to cognitive 
impairment that is a common characteristic in, for example, Alzheimer’s disease (AD), 
schizophrenia and attention deficit hyperactivity disorder (ADHD) [9]. 
Support for the involvement of the nAChR system in nicotinic addication comes from the 
over-representation of tobacco smokers in schizophrenic [9] and ADHD patient groups [10], 
which suggests that patients alleviate attention deficit symptoms by smoking cigarettes. More 
direct evidence from the use of nicotine patches confirms that it is nicotine, the main 
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psychoactive ingredient in tobacco, that is responsible for the effects and, combined with 
results from animal models, there is solid evidence for pro-cognitive effects of nicotine and 
other nicotinic agonists [11].  
 
1.2.1 Physiological function of nAChRs 
 
The broad distribution of nAChRs in the CNS suggests that these receptors play a major role 
in brain physiology. nAChRs functions include cognitive performance, addiction, attention, 
etc. For example, cholinergic cells located in the basal forebrain are thought to have a role in 
memory and arousal [1].  
 
There is evidence that α4 and β2-containing nAChRs are involved in the central 
dopaminergic system. It was found that β2-containing nAChRs reinforce and contribute to 
nicotine response, which stimulates DA release [12].  In an electrophysiology study, Piciotto 
et al. showed that mesencephalic dopaminergic neurons from mice lacking the β2 subunit no 
longer respond to nicotine, and that self-administration of nicotine is attenuated in these 
mutant mice.  
 
A number of studies highlight the crucial role of nAChRs in learning and memory. Kumari et 
al. [13] studied human behavioural performance and blood oxygenation level-dependent 
regional brain activity using functional magnetic resonance imaging. Their study involved 
administration of either nicotine or saline to healthy nonsmoking men who were then given 
an “n-back” task. This is a working memory test in which subjects are asked to check 
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different characteristics of a  stimulus and to report when the presented stimulus is the same 
as the one presented in previous trials  [14].   
  The results indicated better performance in terms of response accuracy over all trials after 
the administration of nicotine rather than the placebo [13]. An increased response after taking 
nicotine was observed in areas activated by the task such as anterior cingulate, superior 
frontal cortex, superior parietal cortex, parahippocampal gyrus and cerebellum. Poor learning 
and performance was also revealed in mice that lacked β2 nAChRs [15]. Another study 
conducted by Levin highlighted the importance of α4β2 nAChRs in memory [16]. He 
induced working memory deficits by blocking ventral hippocampal α4β2. These deficits were 
reversed by chronic systemic nicotine administration. This therapy did not, however, reverse 
similar working memory deficits induced on ventral hippocampal α7.  
 
Another study investigated the effect of mecamylamine (a non-competitive nicotinic 
antagonist) on attention processes such as alerting, orienting and executive control in 12 
healthy male subjects  using a magnetic resonance imaging scanner [17]. The results 
confirmed an association between the activation of some neural networks with attention 
components and a reduced response time to the task following administration of 
mecamylamine. Although mecamylamine is a non-selective nAChRs antagonist, its effects 
indicate that blocking the nAChRs has an impact on cognition and attention and that nAChRs 
may have significance in other CNS-related pathologies in general.  
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1.2.2 nAChRs dysfunction and neuropathologies  
 
A number of CNS pathologies were reported to be directly or indirectly linked to nAChRs 
dysfunction. Disorders such as AD, ADHD, depression and anxiety, schizophrenia, and 
Parkinson diseases (PD) were found to be associated with physiological nAChRs 
abnormalities [18-23].  The following section discusses different neuronal pathologies and 
the role of a4b2 nAChR subtype in particular. 
I.2.2.1 Alzheimer’s disease 
Alzheimer’s disease is the most common neuro-degenerative disorder [24]. It is the leading 
cause of dementia contributing to 50-70% of cases [25]. Itscharacteristics include memory 
and cognitive loss.  These AD symptoms are thought to result from a deficiency in some 
nAChRs subtypes. Both in vitro and in vivo studies have shown a deficit in some nAChRs 
subtypes in AD patients. For example, measuring nAChRs in the AD patient’s brain using 
PET and an analysis of an AD brain tissue indicated an important reduction of α4 subtype up 
to 47% [26, 27]. Another study compared two groups―non-smoking patients with AD and 
non-smoking healthy individuals―by measuring levels of α4β2 nicotinic acetylcholine 
receptor binding. This study showed a significant alteration in the amount of α4β2 receptors 
in the group with AD [22]..  It has been reported that 50% or more of α4β2 nAChRs are lost 
from the neocortex and hippocampus of patients with advanced AD [28].  
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This remarkable loss of α4β2 nAChRs in patients with AD justifies research into the 
development of molecules that target those receptors. Overall, the evidence cited above 
indicates that deficits in α4β2 nAChRs might be early phenomena of AD, which emphasises 
the importance of nAChRs as a potential target for drug development and research. 
1.2.2.2 Nicotinic addiction 
Nicotine is the main addictive compound in tobacco smoking. Tobacco smoking has been 
identified by the World Health Organisation (WHO) as the second leading risk for mortality 
worldwide [29].  According to the WHO, six million people die every year as a result of 
tobacco smoking. Despite its harmful effects, smoking continues to increase particularly in 
low and middle income countries and it remains a growing risk factor for mortality. Nicotine 
addiction has been a major problem for individuals who have attempted to quit smoking [30].   
At the molecular level, nicotine has high affinity with α4β2 nAChRs [31, 32]. These 
receptors are assumed to be highly associated with smoking addiction due to their abundance 
and wide distribution in the brain. The implication of α4β2 nAChRs in nicotine addiction has 
also been reported in several studies. One study aiming to evaluate the role of α4β2 nAChRs 
in nicotinic addiction was performed in monkeys [31]. These α4β2 receptors were measured 
at baseline using radioligand 2-[18F] fluoro-A-85380 (2-FA) and PET. Motivation to self-
administer nicotine was also measured. Findings suggested that the monkeys with a higher 
motivation to self-administer nicotine also had the lowest expression levels of α4β2 nAChRs. 
Other studies highlight the role of α4β2 nAChRs agonists in relief from tobacco craving and 
withdrawal symptoms resulting from smoking cessation [32]. For instance, in a double blind 
randomised clinical trial using varenicline, which is an α4β2 nAChRs partial agonist, 
varenicline was shown to be more effective in management of tobacco addiction and 
improving withdrawal symptoms. 
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In summary, the studies cited above show that α4β2 nAChRs play a major role in expressing 
nicotinic addiction and molecules targeting those receptors could be exploited as potential 
drugs for smoking cessation. 
1.2.2.3 Attention deficit hyperactivity disorder 
ADHD is one of the most common childhood psychiatric disorders and can also persist into 
adulthood [33]. Children with this disorder have abnormal behavioural symptoms such as 
inattention, impulsivity and hyperactivity.  Among adults, the common characteristics of the 
disorder include forgetfulness, difficulty completing tasks, problems with prioritisation, and 
inability to self-monitor behaviour [34]. 
Evidence shows that nicotinic addiction has high correlation with ADHD and that α4β2 
nAChRs are affected. For example, the likelihood of being a regular smoker was examined in 
a longitudinal retrospective study involving self-reports from patients with ADHD symptoms. 
The extent to which ADHD symptoms predicted the age at onset of regular smoking and 
number of cigarettes smoked was also evaluated. Results confirmed a linear relation between 
ADHD and smoking outcome measures (p<0.001) [35]. Another controlled clinical trial has 
demonstrated that ABT-894, an α4β2 nAChRs agonist, is efficacious in reducing ADHD 
symptoms in adults in 243 participants α4β2 agonist [36]. This suggests that molecules that 
activate α4β2 nAChRs are potential useful therapy of ADHD. 
1.2.2.4 Depression and anxiety 
Many scientific papers have reported a connection between nicotine dependence and 
depression. There is also evidence of overrepresentation of depressed individuals among 
smokers and that people who quit smoking often experience immediate depressive symptoms 
as a result of nAChRs desensitisation  [37-41]. 
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A partial nAChRs agonist, lobeline, which is used for smoking cessation and which has also 
been reported to have dual effects of potentiating and inhibiting ACh on α4β2 nAChRs [42], 
was examined for its anxiolytic effects in mice using elevated plus-maze and marble-burying 
tests. Results showed that lobeline has anxiolytic potential effects and suggest that nAChR 
antagonists may be helpful in reducing anxietyin humans [19]. Lobeline was further tested for 
its antidepressant effects on mice using forced swim test, tail suspension test, and novelty 
suppressed feeding test. The behavioural and neuroendocrine results showed that a 
pretreatment of lobeline on mice  demonstrated an antidepressant activity including reduced 
immobility time and feeding latency, significant attenuation of plasmatic corticosterone 
levels, and reduction of norepinephrine and serotonin levels in the prefrontal cortex and 
hippocampus [43]. These observations indicate that molecules known to have affinity with 
a4b2 nAChRs may exert their anxiolytic effects by partly interacting with nAChRs, which 
could be an interesting avenue to explore for further development of novel depression and 
anxiety therapies. 
1.2.2.5 Schizophrenia 
In a study assessing 78 schizophrenic outpatients using the Brief Psychiatric Rating Scale, 
Goff et al. compared current smokers and nonsmokers. Their results showed that 74% of 
patients were current smokers who reported a mean of 19 cigarettes consumed per day. 
Current smokers also reported a higher number of previous hospitalisations and higher doses 
of neuroleptics than nonsmokers [44]. A body of evidence has confirmed that nAChRs are 
decreased in schizophrenics and that the hippocampus, the brain region rich in α4β2, is the 
most affected area.[20]. In a study, density of α4β2 nAChRs in postmortem schizophrenics’ 
brains was examined using [
3
H] cytisine as a radioligand. The findings showed a 30% 
12 
 
decrease in those receptors in the post-mortem striatum of patients with schizophrenia 
compared to controls [45]. This study indicates that α4β2 nAChRs are affected in patients 
with schizophrenia and that smoking seems to be a helpful mechanism for relief from 
schizophrenic symptoms. This suggests the possibility that α4β2 agonists other than nicotine 
might be useful in managing schizophrenia. 
1.2.2.6 Parkinson’s disease 
α4β2 nAChRs are believed to have a relevant relation with the dopaminergic system, which is 
thought to be deficient in PD patients. For example, using cyclic voltammetry to measure 
neuronal firing as a result of dopamine release, Perez et al. evaluated the role of α4β2 
receptors in dopamine release by varying damage in nigrostriatum, a critical region for PD 
[46]. Their findings suggest that single-pulse–stimulated α4β2 nAChRs mediated dopamine 
release decreases to a similar extent with increasing nigrostriatal damage. Another study 
assessed the levels of α4β2 nAChRs using a radioligand in patients with PD with depressive 
or mild cognitive symptoms and compared the results to those from healthy volunteers. The 
results showed a general reduction of α4β2 nAChRs in patients with PD and depression or 
cognitive symptoms. However, reduction of the number of  α4β2 nAChRs binding to 
radioligand was observed in patients with PD and severe or mild cognitive or depressive 
symptoms [23]. Altogether these data suggest that molecules directed to α4β2 nAChRs could 
be important in therapy for PD. 
 
In summary, several neuronal disorders are associated with nAChRs disyfunction. The 
variability of these disorders is an indication of the complexity and diversity of nAChRs as 
well as their broad dispersion in CNS.  
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1.2.3 Subdivision and structure of nAChRs  
 
1.2.3.1 The subdivision of nAChRs  
One of the methods used to characterise nAChRs in the CNS is based on radioligand binding 
studies of the brain [47]. These studies showed the existence of two main classes of nAChRs. 
One class was determined on the basis of sensitivity to the snake toxin αBungarotoxin 
(αBgtx). Bgtx-sensitive nAChRs had affinity with αBgtx at nM level. Another class, referred 
as to AChRs, had affinity with classical agonists such as ACh and epibatidine at nM levels, 
but no affinity with αBgtx.  
Subsequently, molecular cloning studies showed the existence of 12 subunits, α2 to α10 and 
β2 to β4. These combine into αBgtx-sensitive  (α7 to α10) and αBgtx-insensitive receptors 
(α2 to α6 and β2 to β4) [48, 49]. This variety of nAChRs suggests their diverse function 
although they share a common basic structure, which is described in the following section.  
1.2.3.2 The structure of nAChRs 
  
The nAChRs are pentameric ligand-gated ion channels made of transmembrane protein 
complexes [8]. These proteins complexes mediate fast synaptic transmission in the CNS. The 
variation in structure of nAChRs subtypes imparts their unique characteristics and functions 
[50]. These characteristics and functions also depend on the types of subunits assembled to 
form the receptor, the receptor’s location [51], the type and number of binding sites and the 
ligands to which they bind. These properties are discussed in this section and are important 
for understanding their implications of nAChRs in diseases and the design or development of  
new molecules. 
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The most detailed information about the structure of nAChRs has been provided by recent 4 
Ǻ electron images of the receptor in the postsynaptic membranes of the marbled electric ray 
Torpedo marmorata [52]. The receptor consists of a ring of five subunits, Each subunit is 
made up of an N-terminal extracellular domain on which a ligand binding domain (LBD) is 
located, four hydrophobic transmembrane segments (M1-M4) and two hydrophilic loops 
(M2-M3), a large loop that varies in size and sequence between subunits and at which 
phosphorylation sites are located, and a C-terminal end with a hydrophilic extracellular 
segment (Figure 3) [47, 50, 53].  
 
 
 
Figure 3. Schematic illustration of nAChR. 
 It shows subunit components (a) which include an extracellular N-terminal, four hydrophobic transmembrane 
domains (M1 to M4) and extracellular C-terminal. Five assembled subunits form a pentameric receptor (b) 
showing the location of binding sites, the direction of ions from the extracellular domain through the pore and 
their passage through the receptor gate towards the cytoplasm. 
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Assembly of different subunits to form a pentameric ion channel results in a funnel- shaped 
complex (Figure 4) made up of hydrophobic residues on the outer side and hydrophilic 
residues on the inner which is suggested to have a role in ion selectivity and permeation. This 
ion channel contains an ion filter that determines which cations to traverse the channel [49, 
54].  
 
Figure 4.Torpedo marmorata’s nicotinic receptor. 
As viewed (a) from the synaptic cleft and (b) parallel with the membrane plane. The ligand-binding 
domain is highlighted in (a) and only the front two subunits are highlighted in (b) (a, red; b, green; g, 
blue; d, light blue). Also shown are the locations of aTrp149 (gold), the main immunogenic region 
(MIR), a small region on the extracellular part of α subunit and major target of the anti-nAChR 
antibodies as well as the membrane (horizontal bars; E, extracellular; I, intracellular). Adapted from 
Unwin [52]. 
 
Although nAChRs have many structure similarities, there exist differences in ligand binding 
and affinity on various subtypes [55]. One reason is the variation in the number of subunits 
assembled and the number of binding sites in the targeted nAChRs subtype. The typical 
example is α4β2 nAChR subtype, which is reported to be predominant in the brain and to 
exist in two different/alternate stochiometries. These characteristics are relevant in studying 
their function and designing molecules targeting α4β2 subtype. 
 
16 
 
1.2.3.3 The α4β2 nAChR structure and its relevance 
The α4β2 subtype is assembled from α4 and β2 subunits in a pentameric arrangement with 
two currently known alternate stochiometries, (α4)2(β2)3 and (α4)3(β2)2 [56]. It is the most 
abundant nAChR subtype in the brain and is estimated at around 90% of nAChRs expressed 
in the CNS in the rodent brain. This receptor subtype is the main target for several ligands 
targeting the nAChRs [50, 57].  
The α4β2 nAChRs are widely dispersed in the brain. These receptors have been localised 
thanks to radio-ligand binding studies. For instance, a study using [
3
H] cytisine, an agonist 
with high affinity at nAChRs, in conjuction with poyclonal antisera, mainly localised 
α4β2 in the rat cortex [57], A similar study also demonstrated that expression of α4β2 
is most important in the thalamus, cerebral cortex and dorsal hippocampus [51, 58].   
It is currently known that the α4β2 receptor can assemble in two different stoichiometries, 
(α4)2(β2)3 and (α4)3(β2)2, containing either two or three α4 and three β2 or two β2 subunits 
respectively [56]. In addition, (α4)2(β2)3 bears only two identical agonist binding sites in 
α4:β2 interfaces whereas (α4)3(β2)2 has a third agonist binding site in the α4: α4 interface in 
addition to two previously known sites in α4: β2 interfaces [59]. Table 2 summarises key 
features of the two stochiometries. 
Pharmacologically, the two stochiometries differ in the way they respond to ACh and other 
agonists. The (α4)2(β2)3 receptor responds with high sensitivity to ACh with a monophasic 
dose response curve. In contrast, the (α4)3(β2)2 receptor is less sensitive to ACh and 
responds to ACh in a biphasic manner [59].  
The specific location of each of the α4β2 stochiometries in the brain is not clear due to 
limitations in existing techniques as well as lack of new methods to study the anatomical 
17 
 
distribution of individual stoichiometry [60]. For example, a recent study of two 
radioligands― [3H]epibatidine and [3H]NS3573―known to differentiate (α4)3(β2)2 from 
(α4)2(β2)3 stochiometries based on EC50 values was unable to distinguish both 
stochiometries as the two radioligands presented in the same way, with a very narrow range 
of affinity, and showed a single binding site model [61]. This difficulty restrains the 
localisation of individual stoichiometry using such radioactively labeled ligands. Moreover, it 
is unlikely that it will be possible to separate (α4)2(β2)3 and (α4)3(β2)2 using other 
techniques such as antibody labeling or in situ hybridisation with cRNA probes or mass 
spectrometry because the two stochiometries share important structural similarities and are 
difficult to separate [59, 60]. 
 Table 2. Brief Comparison of (α4)2(β2)3 and (α4)3(β2)2 Stochiometries 
(α4)2(β2)3 (α4)3(β2)2 
Composed of two α4 subunits and three β2 
subunits 
Composed of three α4 subunits and two β2 
subunits 
Bears two identic binding sites at α4:β2 
interface 
Bears two identic binding sites at α4:β2 
interface and one binding site at α4:α4 interface 
High sensitivity to ACh, EC50= 1.6µM 
Concentration–response data: Fit very well to 
a monophasic Hill equation,  
Low sensitivity  
Concentration–response data: Best fit biphasic 
Hill equation, with both high EC50_1= 0.95µM 
and low EC50_2= 83nM ACh sensitivity 
components.  
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The organisation and structure of the binding sites in the (α4)3(β2)2 and (α4)2(β2)3 receptors 
are discussed in detail in the next section. Emphasis is on the presence of the additional 
binding site in (α4)3(β2)2, which offers an opportunity for development of novel therapeutics 
targeting these receptors. The work presented in this thesis focuses on the binding properties 
of nAChR constructed with α4 and β2 receptor subunits.  
1.2.3.4 nAChRs agonists binding sites  
Structural studies suggest that the agonist binding site on nAChRs is located at the interface 
between two adjacent subunits in LBDs at the extra cellular N terminal. In heteromeric 
receptors, it is believed that the principal (+) part of the binding site is always formed by the 
α-residues, which binds to the cationic end of agonists[62]. This binding site consists of a 
cation-π interaction with one of several conserved aromatic residues and typically a hydrogen 
bond from the N
+
H of the drug to a backbone carbonyl. The complementary (-) part is formed 
by residues of the neighboring non α subunit. Previous work has shown that it involves a 
hydrogen bonding interaction with the hydrogen bond acceptor of agonist[63]. Thus the 
agonist binding sites on (α4)2(β2)3 nAChRs are located between the principal interface of α 
subunits and the complementary interface of β2subunits (Figure 5). In the case of two 
neighboring α subunits such as in (α4)3(β2)2 receptors both principal and complementary 
interfaces are on each of the α-α interfaces and the number of binding sites is equal to the 
number of α subunits [64].  
  
 
 
Figure 5. Illustration of (α4)2(β2)3 and(α4)3(β2)2  receptors.  
The principal (+) and complementary (-) interfaces are shown as well as binding site( ).  
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An early description of nAChRs binding sites was based on radiolabelling experiments on the 
torpedo [49, 65]. The results led to exploration of the ACh binding sites, which were found to 
be expressed by aminoacids located in the LBD.  Although the study of nAChRs from 
torpedo has elucidated the organisation and full length of nAChRs, the crystal structure of 
AChBP has shown a unique and well-suited model to study the receptor-ligand interaction 
[62]. In fact, AChBP has a binding pocket for agonist that is most similar to the binding 
pocket of nAChRs.    
The AChBP has very close similarities to nAChRs alpha subunits, and most residues 
involved in ligand binding within nAChRs are conserved. As a result AChBP nAChRs share 
common agonists including ACh and antagonists such as d-tubocurarine [62, 66]. It is 
suggested that the ligand binding site on AChBP nAChRs is made of residues in a cleft 
formed by a series of loops named A to F. It is believed that the residues from loops A- C 
contribute to the principal interface of the binding site and residues from loops D-F contribute 
to the complementary interface. 
 
One of the most recent studies has reported the crystal structure of ACh bound to AChBP 
from Lymnaea stagnalis (Figure 6). This study has shown that the ligand  relevant residues 
implicated in ACh binding include Tyr89, Trp143 and Tyr185 residues from respectively 
loops A, B and C on the principal binding interface, cation-π interaction between ACh and 
Trp53 from loop D on the complementary side and ACh hydrogen bond mediated by water 
molecule to Leu102 and Met114 residues of the AChBP [67]. 
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A   B  
 
Figure 6: Structure of ACh bound to Ls-AChBP.   
(A) Side view of cartoon representation of the Ls-AChBP with ACh (green stick). The ACh molecule 
is located between the principal side of the binding pocket, (+) interface (green) and the 
complementary side, (-) interface (orange); and  
(B) ACh bound to Ls-AChBP, as reported here, with principal side-chain carbon atoms in green and 
complementary side chain carbon atoms in orange. Adapted from Olsen et al.[67]. 
 
   
1.2.3.5. Additional nAChRs binding sites 
 
A recent study found that (α4)3(β2)2 receptors have an agonist binding site in α4α4 interface 
in addition to two other known binding sites in α4β2 interface [59]. This additional binding 
site has particular characteristics and structure. For instance, it was documented that ligands 
of a particular size could not bind to the α4α4 binding site of the (α4)3(β2)2 nAChRs, which 
can result in decreased efficacy [68]. It is also argued that the binding site in a α4α4 interface 
needs to be occupied by an agonist to observe a full response. Moreover, Harpsoe et al. have 
demonstrated that three residues found in the α4α4 interface are different from residues in the 
α4β2 interface [59]. Illustration of these three key bind site residues distinguishing α4α4 and 
α4β2 binding sites has helped to understand the pharmacology profiles of the α4β2 nAChRs 
agonists. The three residues were found to be His142, Gln150, and Thr152 in α4, and Val136, 
Phe144, and Leu146 in β2.  
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Interestingly, they were able to convert α4α4 (-) interface into α4β2 (-) like interface and vice 
versa by inducing triple mutation (3M) of the above-mentioned residues [59]. The 
mutations―H142V, Q150F and T152L on (-) 4 side make an α4α4 binding site resemble an 
α4β2, and the mutations―V136H, F144Q and L146T on (-) β2 interface make an α4β2 
binding site resemble an α4α4. Therefore, the (4)3(23M)2 receptor contains one native 
α4α4 site and two α4α4-like sites whereas the (43M)3(2)2 receptor contains two native 
α4β2 sites and one α4β2-like site (Figure 7). The engineered receptors are denoted 
43Mβ2and 423M receptors, indicating that they contain three mutations in α4 and β2 
subunits, respectively.  
       
 
 
 
 
Figure 7. Illustration of engeneered (α4)3(β23M)2 and  (α43M)3(β2)2 receptors. 
A triple mutation (3M) on (-) interfaces is shown by a small differently coloured section on 
the receptor. The binding site is shown as a red dot ( ). 
 
An agonist binding on nAChRs is followed by a rapid opening of the transmembrane ion 
channel, which consequently leads to membrane depolarisation [69]. The result of the 
receptor activation and the opening of the ion channel pore is the entrance of cations 
primarily Ca
2+
. By converting acute nAChR stimulation into sustained cellular events, Ca
2+
 
signals are the crucial link between nACh receptors and the downstream processes that 
influence on many neuronal functions[69, 70]. The entry of Ca
2+
 contributes to maintaining 
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the membrane potential depolarization provoked by an agonist. In turn, levels of intracellular 
Ca
2+ 
regulate nAChR activity.   
An increased amount of Ca
2+
 is followed by a chain of reactions or cell signalling (Figure 5) 
resulting in gene expression for different effects including learning, memory and addiction. 
[71, 72]. 
 
 
Figure 8. Key signalling molecules in Ca
2+
dependent nAChR-mediated processes.  
Ca
2+
 from nACh receptor activation can activate adenylyl cyclase (AC), protein kinase A (PKA), 
PKC, Ca
2+–
calmodulin-dependent protein kinase (CaMK) and phosphatidylinositol 3-kinase (PI3K). 
In turn, these phosphorylate downstream targets, such as extracellular signal-regulated mitogen-
activated protein kinase (ERK), which leads to the activation of transcription factors such as the 
cAMP response element-binding protein (CREB) and increases in expression of genes that encode, 
for example, tyrosine hydroxylase (TH) and nerve growth factor (NGF) receptors. The lipid signalling 
cascade that is initiated by PI3K, through phosphorylation of PKB (Akt) is credited with modulating 
the relative activities of neuroprotective and apoptotic factors, such as Bcl-2 and caspases, 
respectively. Adapted from Dajas-Bailador and Wonnacott [72]. 
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1.2.4 Neuronal nicotinic acetylcholine functional states 
The nAChRs were found to exist in at least one of three interchangeable states; active state, 
onset desensitisation and resting states; that define the level of affinity of the receptor for its 
agonist or antagonist [73].  
First, the active state, or state A, is referred to as the open ion channel state. Second, the 
states named I and D ―which are, respectively, two fast onset and slow onset desensitisation 
states―represent a closed ion channel [72]. The third state is the resting state R. Agonists 
were found to have higher affinity with the receptor in state A than in state R. In fact in the 
presence of an agonist, the receptor is more stable in the desensitised state whereas it is more 
stable in the resting state in the absence of an agonist. In contrast, antagonists have higher 
affinity with the resting receptor than in the active state. However, I and D states are 
characterised by respectively high-affinity and very high-affinity binding profiles for both 
agonists and atagonists [74].   
Activation and desensitisation transitions for heteropentameric receptors are reported to vary 
with the molecules bound to the receptors [49, 51, 64, 75]. For instance, the desensitisation 
state was studied on rat α4β2 nAChRs by applying ACh and Nicotine [74]. These α4β2 
receptor full agonists in a concentration range of 0.1-100 µM produced a similar onset time 
constant of 5 seconds. However, the fast recovery for receptors desensitised by ACh was 50% 
compared to 10% for nicotine which means that nicotine showed a longer lasting 
desensitisation than ACh.  
These findings and reported structure differences in α or β subunit in active and desensitised 
states explain the existence of two different populations of α4β2 nAChRs which respond 
differently to the binding of ACh with high or low affinity [73, 74]. Overall, the nAChRs 
exist in different functional states, and characteristics of these states can be different for 
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various ligands bound on the receptors. In this thesis, functional states of α4β2 receptors 
following the application of selected compounds will be discussed. 
1.2.5 nAChRs ligands 
Compounds that bind nAChRs have continued to emerge since the discovery of two well-
known molecules that have high affinity with nAChRs, namely, nicotine occurring in nature 
as an active compound of Nicotiana tabacum, and ACh which was the first neurotransmitter 
to be discovered [76, 77].  
The nAChRs ligands originate from diverse sources including endogenous proteins such as 
ACh, many plant alkaloids such as nicotine, cytisine, d-Tubocurarine, and methyllcaconitine 
and those of animal origin such as epibatidine (a poisonous alkaloid found on the skin of the 
frog Epipedobates anthonyi),  the conotoxins in the venom of the marine cone snail, and 
synthetic ligands such as  tetramethylammonium (TMA) and 1,1-dimethyl-4-
phenylpiperazinium (DMPP) [78].  
 1.2.5.1 nAChRs agonists  
Because of their diversity, the nAChRs subtypes vary in their sensitivity to agonists. A 
typical example is the differential sensitivity of high sensitive receptor (HS) or (α4)2(β2)3 
stoichiometry to ACh and to nicotine, which is about 100 and 10 times higher, respectively, 
than the low sensitive receptor (LS) or (α4)3(β2)2 stoichiometry [79]. Similarly, other 
agonists like epibatidine and cytisine were reported to be more potent at HS than at LS 
receptors. This nonequivalent selectivity and efficacy can partially explain the existence of 
different agonist binding sites on nAChRs and the complexity involved in designing more 
selective agonists [68]. Moreover, ligands may behave as full agonists on one nAChR 
subtype and partial agonists on the other. For example, choline fully and partially activates α7 
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and α3β2 respectively [80]. Nicotine as a classic nAChRs agonist and the structures of some 
other agonists are discussed below. 
 
1.2.5.1.1 Nicotine 
Nicotine (Figure 7) is the main psychoactive constituent of Nicotiana tabacum, a very 
common drug known for its addictive properties [76, 81]. It has been demonstrated that 
nicotine interacts with nicotinic receptors in the brain and has particularly high affinity with 
the α4β2 nAChRs subtype.  
 
Figure 9. Nicotine structure 
 
Pyridine and pyrrolidine rings in nicotine are believed to play an important role in binding to 
the nAChRs [82]. Nicotine binding was evaluated using AChBP (Figure 8), which is the best 
identified model for nAChRs.  
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A  B  
Figure 10. Nicotine binding to AChBP  
(A) The nicotine binding site shown with ligand in ball and stick,  electron density (SigmaA 
weighted) superimposed, and residues in the binding site in light yellow (principal side) and light blue 
(complementary side). 
(B) Contribution of Asp85 to ligand binding: The charge compensation of (A) nicotine (pink carbons) 
could be aided by the stabilisation of the Trp143 carbonyl oxygen by an Asp85 (green) charged 
hydrogen bond. The yellow dashed lines indicate the hydrogen bonds. Adapted from Celie et al. [82]. 
 
 
It was suggested that the high affinity of nicotine to nAChRs could be a result of close 
packing of its aromatic groups and that hydrogen bonds between the nicotine pyridine ring 
and residues Leu102 and Met114 at the side chain  as well as the nicotine pyrrolidine ring 
and  carbonyl group  of Trp143 [82]. 
Chronic application of nicotine to nAChRs has been shown to be a cause of receptor 
desensitisation and up-regulation [81, 83-86]. It was found that the number of (α4)2(β2)3 
nAChRs subtypes is increased two-fold by chronic application of nicotine. This up-regulation 
is thought to be a result of multiple mechanisms and is believed to be the cause of nicotine 
addiction. In fact, the desensitised and increased number of nAChRs in nicotine smokers 
leads to an increased need for nicotine to keep the receptors occupied and counteract 
withdrawal symptoms [87]. Although nicotine is reported to be a risk factor for serious 
diseases in smokers, including lung cancer and cardiovascular disease, its activity on nAChRs 
is partly associated with beneficial effects such as improving cognition and increasing 
alertness [9, 88, 89].  
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Drug discovery research suggests nicotine as a lead compound for potential drugs for 
neurodegenerative diseases like Alzheimer’s and Parkinson’s. For instance, studies of 
nicotine’s structure have demonstrated that modifying the linker between pryrodine and 
pyrrolidine resulted in safer, more potent and higher affinity nAChRs ligands than nicotine 
[90-92]. Some of the nicotine-derived compounds such as 2-methyl-3-(2-(S)-
pyrrolidinylmethoxy), pyridine dihydrochloride salt (ABT-089) and (S)-3-Methyl-5-(1-
Methyl-2-Pyrrolidinyl) Isoxazole (ABT-418) have displayed significant anxiolytic and 
cognition-enhancement effects.  
In short, nicotine analogs with partial agonist or antagonist properties at α4β2 nAChRs could 
be useful in the treatment of nicotine dependency [93]. In fact, a full agonist such as nicotine 
administered simultaneously with a partial agonists would not produce an agonist maximum 
effect as some receptors are occupied by a partial agonist [94]. By contrast, a full antagonist 
will stop an agonist from binding on the receptor. This is significant when considering the 
fact that α4β2 receptor is important for normal cognitive functions in different parts of the 
brain, so the complete antagonism might result in adverse effects on other brain functions. 
Thus, partial agonists could theoretically offer benefits over either full agonists or full 
antagonists. 
1.2.5.2 nAChRs antagonists 
There is evidence that nAChRs antagonists have potential theurapeutic uses in controlling 
neuronal disorders, but less work has been done to discover novel competitive or non-
competitive antagonists of the brain nicotinic receptors [95]. Most of the available nAChRs 
antagonists seem, however, to be non-selective. This lack of selectivity of nAChRs 
antagonists, in addition to the beneficial effects, is linked to unwanted effects that could limit 
their use. For instance, mecamylamine , which is a non-competitive antagonist at both central 
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and peripheral nAChRs, has been shown to relieve the symptoms of smoking withdrawal [96, 
97]. It is not surprising that the non-selectivity of mecamylamine has led to other clinical 
interests such as antidepressant activity [98].   This example and others given below indicate 
that there is a continuing need for more selective antagonists of the nAChRs. 
1.2.5.2.1 Dihydro-β-erythroidine(DHβE) 
The ability to selectively antagonise nAChRs subtypes may permit potential isolation of the 
desired effects in clinical applications. For example, cognitive impairment is a clinical 
condition that can be controlled by acute administration of dihydro-β-erythroidine(DHβE) 
and low doses of methyllycaconitine (MLA), which are selective antagonists for α4β2 and α7 
nAChRs respectively [95, 99, 100].  
 
DHβE is an alkaloid from the plant Erythrina americana that has displayed high affinity and 
selective potent inhibition effects for α4β2 nAChRs [50, 101]. It has been widely studied and 
serves as a reference antagonist for the α4β2 nAChR. Nowadays, structural studies are using 
DhβE as a model for the discovery of novel antagonists [102]. Recently, for example, two 
structurally related  isolated alkaloids, erythravine and 11 α-hydroxyerythravine (Figure 9) 
from Erythrina mulunga were found to have inhibition effects on α4β2 nAChRs at nanomolar 
concentrations [103].   
 
Figure 11. DHβE and related alkaloids 
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1.2.5.3 nAChRs modulators 
The revelation of benzodiazepines as positive allosteric modulators on GABAA receptors 
motivated scientists to explore various compounds that would allosterically modulate 
nAChRs. For instance, galanthamine and physostigmine were successfully identified as 
compounds useful in AD therapy with a mechanism similar to that of benzodiazepines [104]. 
These compounds are suggested to increase the likelihood of ion channel opening induced by 
the agonist or simply to reduce the desensitisation period of the receptor [105]. Molecules 
such as galanthamine and desformylflustrabromine have shown interesting results in 
preventing nAChRs desensitisation by nicotine thus reducing nicotinic addiction  and AD 
[104, 105] 
Ligands such as desformylflustrabromine, which was found to potentiate ACh response on 
the α4β2 subunit at more than 265% [106], are identified as allosteric modulators. Positive 
allosteric modulators (PAM) are ligands that potentiate nAChR agonist response in 
opposition to negative allosteric modulators (NAM) which reduce the nAChRs agonist 
response [107]. Allosteric modulators are therefore defined as compounds that by themselves 
do not activate the receptor, but potentiate or inhibit the agonist response by interacting with 
the binding site other than the known agonist binding site. 
 
In addition to the classic agonist binding sites on nAChRs, other binding sites were found in 
other location different from known LBD [108].  These previously unknown binding sites are 
referred to as modulators binding sites. In studies using chimeric and point-mutated receptors 
techniques, it was found that a compound encoded NS206 binding site was linked to the α4-
subunit transmembrane domain, which is different from the classic agonist binding site 
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located on the extracellular N-terminal. These observations suggest the existence of other 
distinct binding sites in the α4β2 nAChR subunit. 
The modulators binding sites are of great importance in understanding receptors’ behaviour 
and providing an opportunity for rational drug design. Compounds that bind on those binding 
sites were found to have diverse pharmacological properties including receptor selectivity 
and agonist potentiation or inhibition.  
An increasing number of studies has focused on nAChRs modulators. A recent study has 
shown that two compounds, desformylflustrabromine and galantamine, both of which are 
PAM at α4β2 nAChR, decreased nicotine self-administration in a rat model, which suggests a 
possible target for nicotinic addiction therapy [109]. Table 3 displays some examples of 
known compounds that modulate nAChRs. 
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 Table 3. Modulators of nAChRs  
Examples as adapted from Pandya, A. and J.L. Yakel [110] 
Zn
2+
 Potentiates α2, α3, α4 containing nAChR,  
Significantly potentiates of α4β4, but inhibits α3β2 and α7 receptors 
Modest potentiation of α4β2 receptors. 
17-β-estradiol
 
 Naturally synthesised steroids (progesterone, testosterone, estradiol, 
corticosterone). 17-β-estradiol exerts allosteric effects on 
heteromeric α4 containing nAChR; the effects are generally 
inhibitory at low concentrations. 
 Galantamine 
 
Galantamine which is AChE inhibitor has been shown to potentiate 
α4β2, α3β4, and α6β4 nAChRs at concentrations between 0.1 and 
1mM and at concentrations >10 mM galantamine was found to 
inhibit responses. 
Desformylflustrabromine (dFBr)
 
PAM of α4β2 nAChR. dFBr is one of the few known compounds 
capable of discriminating α4β2 from other nAChR subtypes to 
produce selective potentiation of responses. 
 
In conclusion, the discovery of molecules that modulate α4β2 nAChR represents an important step 
towards a therapy for neuronal disorders [104, 105, 109, 111]. The use of nAChRs allosteric 
modulators increases the probability of receptor opening induced by agonists and decreases 
receptor desensitisation [104, 105]. Furthermore, the use of a modulator has potential clinical 
benefits as the response on nAChRs is reached with a much lower concentration of the 
agonist, thus minimising the agonist’s unwanted effects.  
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This thesis explored reported effects of choline in modulating ACh responses on nAChRs. 
This modulation of ACh effects by choline was investigated with particular focus on α4β2 
receptors. A general overview of knowledge about choline is presented below.  
 
1.2.6 Choline and its derivatives 
 
1.2.6.1 Choline biochemistry 
The chemical name of choline is trimethyl-beta-hydroxy-ethylammonium (Figure 10). It is a 
quaternary ammonium compound which is known to be widely distributed and has a 
prominent biochemical role in the cells [112, 113]. Most importantly, choline is required in 
the synthesis of the phospholipids in cell membranes, cholinergic neurotransmission, 
transmembrane signalling, and lipid-cholesterol transport and metabolism. It is believed that 
the cells die from apoptosis due to lack of choline.  
 
Figure 12. Choline structure. 
(trimethyl-beta-hydroxy-ethylammonium). 
 
In physiological conditions, choline concentrations in the human brain range between 10 and 
20 µM in the normal condition and may increase up to 100 µM in pathological conditions 
such as AD and seizures [114-116]. Other experiments have shown that free choline levels in 
rat brains vary between 30 and 60 µM [3]. It has also been found that there was no variation 
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of choline concentration in the brain as a result of oral administration of choline [117], which 
suggest that the brain has a source of choline other than diet. 
 
Choline in the cells has a dual origin, as a nutrient and by denovo biosynthesis. Although 
several papers have categorised food rich in choline and identified possible consequences of 
choline-deficient diets, such as hepatic steatosis, there is no evidence that adult cholinergic 
neurons require dietary choline to synthetise ACh [112, 113]. Rather, it has been 
demonstrated that the reuptake of intrasynaptic choline is the limiting factor controlling ACh 
synthesis by blocking the reuptake process using hemicholinium-3. However, no food or 
endogenous molecule has shown the same ability [118, 119].  
Endogenous choline exists in the form of phosphatidylcholine, which accounts for 95% of the 
total choline in mammalian tissue [120]. The remaining 5% is present as various species such 
as choline itself, phosphocholine, glycerophosphocholine, cytidine 5-diphosphocholine 
(CDP-Choline) and acetylcholine. The phosphatidylcholine form is biosynthesised in the 
mitochondria through the sequential methylation of phosphatidylethanolamine by S-adenosyl 
methionine (SAM) in the methionine cycle by phosphatidylethanolamine methyltransferase 
(PEMT). In the cholinergic neurons, choline is derived from three main sources (Figure 11) 
[3, 121]. In the first source, choline is brought into neurons by a low affinity transport 
mechanism, maintaining equilibrium between circulating choline in extracellular fluid and 
choline in other brain cells. The second source consists of choline formed by ACh hydrolysis 
by AChE in the synaptic cleft; choline is then taken up by a high affinity transport 
mechanism. The third source is believed to be choline-related bases, and the mechanism 
consists of base exchange or phospholipase mediated hydrolyses.  
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Figure 13. Sources of choline for neurons in the brain.   
Choline from extracellular fluid is transported in neurons by a low affinity transport mechanism (1). 
Choline resulting from hydrolysis of AChE in the synaptic cleft is taken up by a high affinity transport 
mechanism (2). Choline is liberated by base exchange (5) or phospholipase mediated hydrolyses (6 to 
13). This figure was adapted from Blusztajn and Wurtman [3].  
 
 
The high affinity transport of choline from the synaptic cleft predominantly occurs at 
presynaptic cholinergic nerve terminals, with an average affinity for choline between 0.1-10 
µM [118, 119, 122]. The low-affinity transport, which is mainly for phospholipid synthesis, 
has an average affinity for choline between 30-100 µM and is a sodium-independent carrier 
mediated uptake. By contrast, the high-affinity transport is a sodium-dependent carrier-
mediated uptake and the most important source of choline for the cholinergic neuron to 
synthetise ACh. 
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Taken together, these findings show that choline is essential to maintain normal conditions of 
various functions particularly protecting neurons and a normal cholinergic neurotransmission. 
Cholinergic neurons also have a mechanism for reproducing choline, which partly maintains 
its constant level in the brain. The brain levels of choline were reported to be much higher in 
infants and, most importantly, choline is known to have a prominent role in early CNS 
development, memory and cognition.  
 
1.2.6.2 Choline and nervous system development 
In the first days of life, high levels of plasma choline are reported but these levels decrease 
significantly with increasing age [123, 124]. For example, the serum free choline level was 
measured in humans and was found to be 35.1±1.1 µmol/L at birth, decreasing gradually to 
10.9±0.6 µmol/L a year after birth. It was also reported that plasma concentration in 
newborns was three times higher than in mothers aged between 22 and 36 [123, 125].   
High levels of choline in fetuses, newborns and breast milk explain the exceptional 
importance of choline [123, 125-127].  The choline supply is particularly sensitive during 
critical periods of nervous system development, with evidence of effects on cognition [120, 
128-130]. To demonstrate choline’s role in cognitive performance, studies using animal 
models have shown that prenatal choline depletion is highly correlated with memory deficits 
[128, 130]. For example, male rats were exposed to choline deficient, sufficient or 
supplemented diet during the embryonic stage and thereafter given a controlled diet [131]. At 
the age of 70 days, the rats were given a task to locate eight baited arms of a 12 arm radial 
maze. The results showed that rats who had been exposed to sufficient choline made many 
more choices than rats who had received the deprived or supplemented choline diet.  
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All these data show that choline enhances cognition and memory function in early age, but 
this role is not yet clearly established in adults. However, it is known that choline activates 
nAChRs [132] through which cognition and memory functions are partly expressed. 
Although it is not yet known whether choline may activate nAChRs under physiological 
circumstances, some evidence supporting the interaction of choline with different nAChRs 
subtypes has been reported. 
I.2.6.3 Choline and nicotinic receptors 
The role of choline in the early CNS development has been widely discussed in the literature 
[130]. These functions, particularly learning and memory, are known to be mediated by 
nAChRs [22]. However, little is known about the specific mechanism through which choline 
influences cognition and its interaction with receptors in the brain[132]. Early study 
demonstrated the agonistic effect of choline on cholinergic receptors, but its potency was 
perceived to be too low to impact the CNS [132]. Moreover, a number of quaternary 
ammonium compounds including choline were reported to have pharmacological activities 
similar to those of muscarine and nicotine actions in the CNS.   
 
Choline was found to be a full and selective agonist of the α7 nAChR subtype and a weak 
agonist for α3β4 (Table 4);  no activation was seen on α4β2 subtypes [80]. Nevertheless, the 
choline regulating effects of nAChRs have been investigated and the inhibitory potency of 
choline on α3β4 was found to be higher than on α4β2 [133, 134]. Moreover, a dual effect of 
choline co-applied with ACh was observed on α4β4 nAChRs [135]. It was shown that a low 
concentration of choline potentiated responses evoked by 1 µM ACh, but inhibited by 300 
µM and higher concentrations of choline (Table 4). This is believed to result from the 
competitive and noncompetitive effects of both ligands. Most recent data have shown that 
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choline regulates hippocampal network activity, which is mediated in part by α7 nAChR 
[136].  Another study has revealed that choline induces α4 and β2 nAChR subunits 
upregulation, and it is believed that this upregulation could be a response to altered metabolic 
and inflammatory conditions [137].  
Table 4. Reported effects of Choline on different nAChRs subtypes  
  Choline effects 
nAChR subtype Effect/potency  Potentiation Inhibtion 
Rat 7 [80] 
Selective full 
agonist,  
  
  
EC50 = 1.6 mM 
Bovine 7 [134] 
A weak full 
agonist,  
  
  
EC50 = 0.43 mM. 
Bovine 3β4 
[134] 
 Voltage-
dependant 
inhibition; 
 
  
IC50 = 0.97 mM 
Rat 3β4 from 
hippocampal and 
dorsal striatal 
slices [133] 
  
ACh Potentiation by  
choline <3 µM 
ACh Inhibition by  
choline >3 µM,  IC50 
of 15µM 
Rat4β4 
expressed in 
Xenopus oocytes 
[135]
  
 Choline enhanced  
responses evoked by 1 
µM of ACh 
ACh 300 µM  was 
inhibited by   choline, 
IC50 = 0.87mM 
Rat 4β2 from 
hippocampal and 
dorsal striatal 
slices [133] 
   
ACh 100µM was 
inhibited by 200 µM 
to 10mM of  choline,  
IC50=372 µM   
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In summary, the data reported above suggest that choline has the ability to interact with nAChRs and 
has major effects on the developing brain. It is particularly noted that free choline present in 
synaptic fluid following neuronal depolarisation may or may not attain levels sufficient to 
activate the nAChRs. Although interaction of choline with brain receptors including α4β2 is 
reported, the effect of choline on different stochiometries of α4β2 nAChRs is not yet known.  
In the present study, choline concentrations relatively comparable to those found in the brain 
were administered on α4β2 nAChRs in order to produce more robust scientific evidence of 
the effects of choline, which could lead to better understanding of its role in the brain.    
1.3 Aim and Significance of the Study  
 
The overall aim of this study was to evaluate choline activity on different stochiometries of 
α4β2 nAChRs in the presence or absence of ACh using electrophysiology techniques. As 
previously noted, choline plays two roles: as precursor and metabolite of ACh. It is believed 
that the two molecules cohabit in the synaptic cleft once the release of ACh is stimulated.  It 
is therefore hypothesised that certain amounts of choline compete with ACh on postsynaptic 
nAChR.  Understanding the effect of choline on specific nAChR and its competition with 
ACh on the same receptors would be an important contribution to current knowledge. Such 
information is essential to understand nAChR signaling in vivo and for the development of 
new ligands and may eventually translate into the design of novel therapeutics.   
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1.3.1 Specific objectives  
 
The study had three specific objectives:  
 To investigate the effect of choline on currently known α4β2 nAChRs stochiometries, 
(α4)3(β2)2 and (α4)2(β2)3. This will show whether choline activates or not each of 
those stochiometries. The (α4)3(β2)2 and (α4)2(β2)3 contain respectively one and no 
α4α4 binding site, therefore this study will determine the impact of α4α4 binding site 
on the efficacy and potency of choline on those receptors. 
 To determine the efficacy and potency of choline on engineered α4β2 nAChRs. The 
α4β2 engineered receptors consist of (4)3(23M)2 and (43M)3(2)2, which are 
receptors containing three point mutations (3M) on complementary α4α4 and α4β2 
binding sites where key amino acids involved in receptor binding are different [59]. 
As explained earlier, mutating the (-) 4 side makes an α4α4 binding site resemble an 
α4β2, and an α4β2 binding site resemble an α4α4. Therefore, the (4)3(23M)2 
receptor contains one native α4α4 site and two α4α4-like sites whereas the 
(43M)3(2)2 receptor contains two native α4β2 sites and one α4β2-like site. The 
advantage of using these receptors is is that it allows the effects of the ligand on either 
the α4α4 or α4β2 binding site to be investigated separately. Experiments on 
engineered receptors could reveal then choline selectivity between α4α4 and α4β2 
binding sites. 
 To investigate the co-application of choline and ACh on (α4)3(β2)2. This will extend 
our understanding of the physiological role of the α4α4 interface, as well as the 
choline potentiation or inhibition of ACh responses. The co-application of ACh with 
choline pre-incubation is also taken into account in order to observe any change in 
potentiation or inhibition effects.   
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Chapter 2 
Materials and Methods 
 
 
2.1 Materials 
 
The wild-type rat plasmid cDNA (Table 3) encoding α4 and β2 nAChR subcloned into pSP64 
cloning vector from SP6 polymerase promoter (Figure 14) were stored in the molecular 
biology laboratory of the Faculty of Pharmacy, The University of Sydney. The α4 and β2 
nAChR mutants were generously engineered and donated by Denish Indurth, and were stored 
in similar conditions. All enzymes and compounds choline and ACh used as ligands were 
obtained from the Faculty of Pharmacy, The University of Sydney. Oocytes of a female 
Xenopus laevis, a species of South African frog, were imported and housed in the Edward 
Ford Building (Room number 117, Building A27A, The University of Sydney). 
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Table 5. Plasmid cDNA Vector, RNA Polymerase and Linearisation Restriction Enzyme 
for each nAChR Subunit 
Plasmid 
cDNA 
Plasmid cDNA Vector Polymerase Promoter Linearisation Enzymes 
4 pSP64 SP6 EcoRI 
2 pSP64 SP6 HindIII 
  
 
 
 
Figure 14. A map of pSP64 Cloning vector for in vitro transcription from the SP6 promoter  
with the addition of a synthetic 30-base poly(A) tail, author: Promega.
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2.2 Molecular Biology Methods 
 
2.2.1 Transformation of DNA plasmids  
 
Rat nAChR cDNAs were transfected into one shot Top 10 chemically competent cells 
and ampicillin-resistant E.Coli using aseptic techniques. This was done by adding 1-5 
µL of cDNA plasmids (Table 4) to 50 µl E,Coli cells and the mixture was incubated 
on ice (0°C) for 30 minutes. During this period the plasmid cDNAs were adhering to 
the E.Coli cell wall. The cells were then incubated for exactly 30 seconds in the 42°C 
water bath. This heat-shock creates pores on the cell wall and the plasmids are able to 
enter the cells [138]. The cells were then placed on ice for 2 minutes to restore the cell 
wall integrity. 
 
2.2.2 Culturing the transformed E.Coli cells  
To grow transfected E. coli cells, 250 µL of pre-warmed S.O.C medium 
(bactotryptone 20g/L, bactoyeast exctract 5g/L, NaCl 0.5g/L, 2,5mM KCl (pH 7.0), 
10mM MgCl2, 20mM glucose) was aseptically added to the cells and incubated in a 
shaking incubator (Orbital Mixer Incubater, OM-11; Ratek Instruments, Boronia, 
Vic., Australia) at 225 rpm at 37°C for an hour.  Next, the incubated cells (100 µL) 
were spread on fresh lysogeny broth (LB)-agar plates containing ampicillin (100 
µg/mL) to limit bacterial contamination (E. coli cells are ampicillin-resistant) and 
incubated overnight at 37°C. Isolated E. coli colonies were randomly selected from 
the LB-agar plate and added to LB-broth containing ampicillin (100 µg/mL). The 
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mixture was then incubated in the shaking incubator overnight (at least 15 hours) at 
37°C.     
 
2.2.3 Purification of plasmid DNA  
 
The plasmid DNA was purified using the QIAprep Spin Miniprep Kit (QIAGEN). E. 
coli cells 5mL were collected by centrifugation at 14,000 rpm for 2 minutes at room 
temperature in Eppendorf tubes. A cells pellet was formed, the supernatant was 
discarded and the cell pellet was resuspended in 250 µL of buffer P1 (50mM Tris 
(pH7.5), 10mM EDTA, 100 µg/mL RNase A), then 250 µL cell lysis solution buffer 
P2 (200mM NaOH, 1% SDS) was added to solubilise the cell membrane protein and 
phospholipids, which results in release of the cell content. The cell lysis solution was 
then neutralised by adding 350 µL of buffer N3 (1.32M CH3COOK pH4.8). A 
precipitation was then formed in which denatured and chromosomal DNA were 
trapped while the plasmid DNA remained in the solution due to their smaller size. The 
plasmid DNA and the cellular debris were separated by 10 minutes centrifugation at 
13000rpm at room temperature. The supernatant obtained, which contained plasmid 
DNA, was then added into QIAprep spin column and centrifuged for 60 seconds. At 
the end of this step, the plasmid DNA was bound to the column. The next step was to 
wash the QIA prep spin column. This was done by adding buffer PE 750 µL (10mM 
Tris-HCl (pH7.5), 10mM EDTA) and centrifuging for 60 seconds. The flow through 
was then discarded and the spin column was centrifuged again for 60 seconds to 
eliminate ethanol residue. Finally, to elute the plasmid DNA, the QIAprep column 
was placed in a clean 1.5mLcentrifuge tube and elution buffer EB 50 µL (10mM Tris-
Cl, pH8.5) was applied to the centre of the column.  The column and centrifuge tube 
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were allowed to stand for 60 seconds, followed by 60 seconds centrifugation at 14000 
rpm, and the purified plasmid DNA was collected. 
2.2.4 Linearisation of plasmid DNA  
The linearisation and purification of plasma cDNA was done to prepare for RNA 
synthesis. Circular plasmid cDNA was linearised by incubation of plasmids with 
EcoRΙ and HindΙΙΙ restriction enzymes, respectively, for plasmids containing the 4, 
2 inserts at 37 oC for 2 hours. The completion of linearisation of plasmid DNA was 
checked by running an electrophoresis gel. To this end, 2 µL of plasmid cDNA was 
stained with 2 µL of Blue/Orange Loading Dye (Promega ©, Madison, WI, USA) and 
separated along an agarose gel (~1%; supplemented with tris-acetate 
ethylenediaminetetraacetic acid (TAE) and ethidium bromide) using a HE-33 Mini 
Horizontal Submarine Unit (90 mV, 30 to 60 minutes; Hoefer, Inc., San Francisco, 
CA, USA). The plasmids were then visualised with UV light using GelDoc
TM
 1000 
and Molecular Analyst Software (BioRad, Hercules, CA, USA). 
 
Fragment size was estimated by comparison with a 1 kb DNA ladder (Promega ©, 
Madison, WI, USA). These fragment sizes were then compared with the predicted 
fragment sizes, which were calculated from APE-A Plasmid Editor V1.08 for 
verification of linearised cDNA. The linearised cDNA was then purified by adding 5x 
volume of buffer PB to the restriction enzyme reaction and mixed well. The mixture 
was applied to a QIAquick spin column in a provided 2 mL collection tube to bind the 
DNA, and then the spin column was centrifuged for 60 seconds. The flow-through 
was discarded. The purity of linearised DNA was maximised by washing the spin 
columns again with 750 µL of buffer PE, then centrifuged for 60 seconds and the flow 
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through was again discarded. The spin columns were placed again in the tubes and 
centrifuged for an additional 60 seconds. The QIAquick columns were put in clean 
microcentrifuge tubes and the DNA was eluted by adding 50 µL of buffer EB to the 
centre of the tube and left standing for one minute to increase the concentration of 
eluted DNA, and the DNA was collected by 60 seconds centrifugation at 14000 rpm. 
 
2.2.5 Synthesis of mRNA  
The transcription of 4 and 2 mRNAs from linearised cDNA was done using SP6 
polymerase mMESSAGE mMACHINE Kit (Ambion, Austin, TX, USA). It involved 
the reaction of a mixture of 6 µl linearised cDNA with 2 µl of 10x transcription 
buffer, 10 µl of 2x NTP/CAP ribonucleotide mix (15 mM adenosine triphosphate 
(ATP), 15 mM cytidine triphosphate (CTP), 15 mM uridine triphosphate (UTP), 
3 mM guanosine triphosphate (GTP) and 12 mM Cap Analog) and 2 µL of 10x 
enzyme mix (including SP6 RNA polymerase and placental RNase inhibitor in 50% 
glycerol). The reaction mixture was then incubated for 2 hours at 37°C to allow 
synthesis of mRNA. The reaction was then stopped by adding 30 µL nuclease free 
water and 30 µL LiCl precipitation solution which resulted in mRNA precipitation. 
The mixture was chilled for 30 minutes at −20ºC. The mRNA was then pelleted by 
centrifugation at 4ºC for 15 minutes at 14000rpm, then washed with 500 µL freshly 
prepared cold 70% ethanol, dried and re-suspended in 15 µl nuclease free water. 
Purified mRNA was stored at -20°C until needed. 
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2.2.6 RNA concentration measurement 
The concentration of obtained mRNA has to be verified in order to ensure the absence 
of contaminants and that the ratio to be injected in the cells is correct. The presence of 
mRNA was verified by heating a sample of mRNA at 94ºC for 1 minute to denature 
the mRNA with an equal amount of gel loading buffer (95% formamide, 0.025% 
xylene cyanol, 0.025% bromophenol blue, 18 mM EDTA, 0.025% SDS). This mRNA 
was run on ~1% agarose gel containing ethidium bromide. The quality and quantity of 
RNA was checked by comparing its band to a standard DNA ladder. 
The quality and concentration of the mRNA was also determined using the NanoDrop 
1000 Spectrophotometer (Thermo Scientific, DE, USA). The 260 nm/230 mm 
absorbance ratio between 2-2.2 indicates pure mRNA. The pure mRNA was further 
diluted to the required concentration with nuclease-free water when necessary. 
 
2.3 Electrophysiology Methods 
 
2.3.1 Preparation of Xenopus laevis oocytes 
The oocytes were obtained by surgically removing ovarian lobes of Xenopus laevis 
under anaesthesia (Tricaine, 850 mg/500 mL), which is done by a trained surgeon on 
a weekly basis.  To get the oocytes ready, the lobes are first rinsed with oocytes 
releasing buffer 2 (OR2; 82.5mM NaCl, 2mM KCl, 1mMMgCl2, 5mM 4-(2-
hydroxyethyl)-1-piperazineethane-sulfonic acid (HEPES) hemisodium salt, Ph 7.5) 
and cut into smaller clusters of cells, then treated with collagenase A (2mg/ml) in 
OR2 and for two hours at 18°C in a shaking incubator (505; Stuart Scientific, UK). 
The defolliculated and separated oocytes are obtained and rinsed with ND96 solution 
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(96mM NaCl, 2mM KCl, 1.8mM CaCl2, 1mM MgCl2, 5mM HEPES hemisodium 
salt, 2.5mM pyruvate, 0.5 mM theophylline, pH7.5). Finally, the best oocytes for use 
(stage V-VI) were sorted and kept in ND96 solution containing 4 µg/ml kanamycin. 
 
2.3.2 Injection of mRNA in the oocytes 
 
The injection of mRNA in the oocytes was done using micropipettes made of glass 
capillaries (0.53 mm I.D.x1.14 mm O.D.; Drummond Scientific Company, PA, USA). 
The micropipettes were prepared by using a microprocessor-controlled micropipette 
puller (PUL-100, World Precision Instruments, Inc., FL, USA). Thereafter, the 
micropipettes were beveled at a tip diameter of approximately 10-20 µm and filled 
with mineral oil. Pre-mixed α4 and β2 wild-types or mutant mRNA in appropriate 
ratios were drawn up the micropipette using negative pressure. Appropriate ratios 
were defined based on previous studies which have demonstrated that different 
proportions of α4 and β2 subunit RNA injected into Xenopus oocytes produce a 
predominance of either isoform whose function and pharmacology match 
concatenated receptors [56, 59, 79, 139]. Thus injected α4 and β2 RNA ratios were 
10:1 or 1:10 which favours the production of (α4)3(β2)2 or (α4)2(β2)3 receptors 
respectively. Using a Nanoliter 2000 injector (World Precision Instruments, Inc., FL, 
USA), approximately 50 nL of mRNA was injected into the cytoplasm of each 
oocyte; any possible cross-contamination between different ratios was avoided by 
using separate micropipettes. Injected oocytes were kept in ND96 solution 
supplemented with kanamycin 4 µg/ml and incubated in an orbital shaker at 18°C for 
two days before use in the electrophysiology experiments. 
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2.3.3 Two-electrode voltage clamp 
 
Electrophysiology studies for the receptors were done using two-electrode voltage 
clamp recording. This is a set-up of a GeneClamp 500 Amplifier (Axon Instruments, 
Foster City, CA, USA), a power lab (AD instruments, Sydney, NSW, Australia) and 
chart version 3.5 program for Macintosh. Two glass microelectrodes (0.94 mm I.D., 
1.2 mm O.D., 150 mm length; Harvard Apparatus, Kent, UK) were pulled from the 
micropipette puller (PP-830, Narishige, Japan), filled with 3 M KCl. Oocytes were 
placed in a cell bath and transfixed with the two electrodes. Oocytes were then 
clamped at 60 mV and continuously perfused with calcium-free buffer as Ca2+ may 
enter receptors and disrupt the results (CF; 115 mM NaCl, 2.5 mM KCl, 1.8 mM 
BaCl2, 10 mM HEPES).  
2.3.4 Ligands application and data recording 
 
The potency and efficacy of ligands were tested on stable oocytes with receptor 
expression. The receptors’ expression was tested by applying the control solution, 
1mM Ach, on the clamped oocyte and then observing the inward induced current with 
a maximum that depends on the receptors’ stoichiometry and type expressed in the 
oocyte. The oocyte was under continual perfusion of calcium-free buffer to keep it 
alive. The solution of a ligand to be tested was then allowed to run on the oocyte until 
a maximal response, shown by the maximum induced current, was obtained. 
The cell stability and response consistency were verified by 1mM ACh every second 
ligand application, and an interval of 10 min washing time was considered after each 
dose application to minimise receptor desensitisation. Increasing concentrations of 
ACh were applied to wild types and mutants of each α4β2 nAChR stoichiometries, 
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and the dose response curves were constructed to confirm their pharmacological 
profile. Pharmacological activity of choline was then evaluated. Increasing 
concentrations of choline were applied to wild types α4β2 and mutants, and induced 
currents were recorded in Labchart 7 Reader (ADInstrument). Then choline was co-
applied with 1µM, 10 µM and 100 µM ACh on the (α4)3(β2)2 stoichiometry. Lastly, 
the effect of 300 µM choline pre-incubation on increasing concentrations of ACh was 
tested on (α4)3(β2)2  nAChR.2.3.5 Analysis of electrophysiological data 
Electrophysiology data were collected as currents elicited by ligand applied to the 
cells. Induced current (I) of the ligand was compared to the current elicited by 
maximum response (Imax) of the control (ACh 1mM), and the average proportion 
I/Imax of currents induced on four to six different oocytes was reported. The 
proportion I/Imax was plotted as a function of ACh concentration and fitted by the 
least squares method to the sigmoid concentration-response (variable slope) equation 
(or Hill equation) (see equation 1) in GraphPad Prism 6 (GraphPad Software, CA, 
USA). Statistical analyses were determined by using a paired student’s t-test. A p-
value for EC50 and Hill coefficient (nH) of <0.05 was determined to be statistically 
significant. 
or 
 
                                                 
 Equation 1. The Sigmoidal Concentration-response Equation.  
(a) Where [A] is the concentration of the agonist compound, EC50 is the concentration that 
activates 50% of the maximum response. IMax is the maximum current elicited by ACh on 
that cell.  
(b) Where [D] is the concentration of the antagonist compound, and IC50 is the concentration 
that inhibits 50% of the maximum response. nH is the Hill coefficient, a measurement of co-
operativity of agonist binding. 
 (a)   I =        Imax [A] 
nH      
.            (EC50) 
nH + [A]
 nH 
(b)   I =        I50 [D] 
nH      . 
            (IC50) 
nH + [D]
 nH 
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Chapter 3 
 
Results 
 
The main objective of the project was to evaluate the pharmacological activity of 
choline and choline in combination with ACh on α4β2 nAChRs. To this end, 
compounds were tested on two stoichiometries of the α4β2 nAChR, (α4)2(β2)3 and 
(α4)3(β2)2. Subsequently, choline was tested on receptors engineered to have either 
α4-α4-like binding sites or α4-β2-like binding sites in order to evaluate the effect of 
choline at the individual interfaces. This chapter begins by presenting results from 
ACh as well as choline application on wild types (α4)3(β2)2 and (α4)2(β2)3 receptors. 
Then the results of choline co-application with fixed concentrations of ACh on 
(α4)3(β2)2 nAChRs are presented, followed by the results from the investigation of 
ACh choline effects on mutant receptors, specifically (α4)3(β23M)2 and (α4
3M
)3(β2)2. 
Finally, results from experiments evaluating the effects of ACh on (α4)3(β2)2 after 
choline pre-incubation are reported. The relevance of the results in a broader 
physiological context and the contribution of the research to the knowledge base of 
neuroscience will be discussed in Chapter4. 
 
3.1 Experimental Data Presentation 
 
In the research experiments, two electrode voltage clamp measurements were used to 
record changes in ion channel conductance following application of different 
concentrations of ligands. Peak current amplitudes were measured and plotted against 
concentration. The concentration-response curves were constructed and are shown in 
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Figures. The data characteristics of the concentration-response curve presented 
include population size (n), maximum efficacy (Imax) and potency (EC50 which is the 
concentration required to produce 50% of the maximum efficacy) along with the 
significance shown in terms of the negative logarithmic value of EC50 and standard 
error (pEC50±SE). Illustrative current traces are also presented as raw data to show the 
changes in current in response to ligand application on the receptors.  
 
3.2 ACh on Wild Types α4β2 nAChRs  
 
ACh was first tested on both (α4)2(β2)3 and (α4)3(β2)2 receptors to confirm that the 
oocytes were expressing uniform receptor from a  mix of α4 and β2 RNA in 1:10 or 
10:1 ratios. On (α4)2(β2)3 receptors a sigmoidal concentration response curve with an 
EC50 value of 3.4M (pEC50±SE = 5.5±0.08), n= 5 was obtained and for (α4)3(β2)2 
receptors the EC50 value was nearly 30 times higher, 100M (pEC50±SE = 3.9±0.09), 
n= 4 (Figure 15A). Visual inspection of the ACh response curve for (α4)3(β2)2 
showed a prolongation of the curve or “tailing” at low concentrations, which is an 
indication of biphasic response curve. This curve was therefore fitted to a biphasic 
Hill equation and statistical analysis that the best fit was obtained with ACh potencies 
of EC50_1=1.64 µM and EC50_2=154 µM,(Figure 15B) for respectively (α4)2(β2)3 and 
(α4)3(β2)2 receptors. These values are similar to those previously reported by 
Harpsoe et al. on (α4)3(β2)2 with α4:β2 expression ratio of 20:1 or 100:1 [59]. These 
results show that our receptor populations, (α4)2(β2)3 / (α4)3(β2)2, were uniform and 
can therefore be used for testing other ligands and that 1 mM ACh can be considered 
as a standard maximal control for α4β2 nAChRs agonists. 
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Figure 15. Concentration-response relationships for ACh on α4β2 nAChRs 
stoichiometries.  
ACh on (α4)2(β2)3 (green) and (α4)3(β2)2 (blue) nAChRs fitted to a monophasic (A) and 
biphasic concentration response curve (B) from ACh on (α4)3(β2)2. Receptor populations 
were obtained by injecting 4 and β2 cRNA into Xenopus laevis oocytes in a 1:10 or 10:1 
ratio to yield (4)2(2)3 and (4)3(2)2 nAChRs, respectively. Peak current amplitudes were 
measured by two electrode voltage clamp electrophysiology, normalised to the control 
response (1 mM ACh) and fitted by nonlinear regression to a monophasic or biphasic Hill 
equations using GraphPad Prism 6. Regression results (Log EC50, Imax) are summarised in 
Table 7 on page71. 
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3.3 Choline on Wild Types α4β2 nAChRs 
 
In an attempt to evaluate the agonist activity of choline on α4β2 nAChRs, increasing 
choline concentrations were applied to wild type (α4)3(β2)2 and (α4)2(β2)3. On one 
hand, choline was tested on (α4)3(β2)2, resulting in inwards currents (Figure 17A) 
which were then measured and the data were analysed to obtain a concentration 
response curve (Figure 16). Results from non-linear regression analysis showed that 
choline is a weak partial agonist with about four percent of the ACh induced maximal 
response, whereas EC50 values revealed that choline is four times less potent than 
ACh. This is evident when choline and ACh response curves are plotted on the same 
figure (Figure 13B).  Choline efficacy is 30 times lower than ACh efficacy and EC50 
values of 0.1mM (pEC50±SE = 3.9±0.09) and 0.4mM (pEC50±SE = 3.35±0.48), (n=6) 
for ACh and choline respectively, show that choline is 4 times less potent. In contrast, 
choline had no activity on (α4)2(β2)3 receptors when applied in concentrations up to 
10 mM (Figure 17B). This suggests that choline does not activate (α4)2(β2)3 
receptors, which may partially explain previously reported data indicating that choline 
does not have any activity on α4β2 hippocampal neurons [80].   
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Figure 16. Concentration-response curves for choline alone and for choline compared to 
ACh on (α4)3(β2)2 nAChRs.   
The receptors population, electrophysiological techniques and data analysis are described in 
the legend to Figure 15.  Cartoon on the right side represents (α4)3(β2)2 receptor. 
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Figure 17. Sample current traces of choline on (α4)3(β2)2 and  (α4)2(β2)3 nAChRs 
expressed in Xenopus oocytes.  
First, the oocyte was treated with ACh 1mM (control in green) and then increasing 
concentrations of choline were applied. The control was always applied after every second 
ligand application and waiting time was 10 minutes before application of the next 
concentration to allow the signal to return to baseline and to allow remaining traces of ACh to 
be washed off. The holding potential was -60mV. 
 
 
 
 
 
A 
B 
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No previous studies relating to choline effects on individual and specific α4β2 
stochiometries were identified in the literature review. However, a few analytical 
studies of some nAChRs are comparable to our findings on α4β2 receptors. For 
example, choline was reported to activate nicotinic receptors in the adrenal medulla, 
resulting in the secretion of catecholamines [132]. Compared to baseline, secretion of 
catecholamines was increased after administration of choline 0.5 mM. In the same 
study, choline was able to displace L-[
3
H] nicotine from nicotinic receptors in various 
regions of the brain such as cortex and hypothalamus with an IC50 range of 0.5mM to 
1.4mM [132], which is the range within which the potency of choline on (α4)3(β2)2 
expressed in Xenopus oocytes in our experiments was. These results could be 
significant as α4β2 nAChRs are predominant in parts of the brain studied although it 
is hard to confirm expression of (α4)3(β2)2 stochiometry due to limitations in 
currently available techniques [61]. 
 
Another study suggested that choline is a weak but selective agonist with full efficacy 
(Imax = 91% of the maximal amplitude evoked by saturating ACh 3mM) on α7 
nAChRs expressed on hippocampal cultured rat neurons with a potency of 1.6mM 
[80]. However when bovine α7 nAChRs were expressed in Xenopus laevis oocytes, 
choline showed two fold higher potency of 0.6 mM [140]. These two different values 
may be explained by the fact that the receptors expressed in the oocytes are much 
more isolated receptors and activated by less concentration of an agonist than the 
concentration to activate receptors expressed in tissue such as neurons because of the 
possible presence of receptors other than those of interest [141]. Contrary to α7, 
choline induced no detectable currents on receptors on hippocampal rat neurons 
bearing α4β2 nAChRs [80].  
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In contrast to observations in the literature, our experiments showed that choline does 
have some effect on α4β2-nAChRs and that the effect is stoichiometry dependent. In 
fact, choline potencies 400 µM and 600 µM respectively on (α4)3(β2)2 and α7 
receptors expressed in Xenopus laevis oocytes are quite equivalent. The big difference 
is that on α7, choline has full agonist efficacy whereas on (α4)3(β2)2 it is a very weak 
partial agonist. Activity on (α4)3(β2)2 but not (α4)2(β2)3 receptors could indicate that 
choline requires α4α4 interface to have an effect. 
To further explore this possibility, we investigated choline efficacy or potency on 
receptors that contain either α4β2 or α4α4 binding sites by exploiting a set of mutant 
receptors engineered to have these features.  
 
3.4 ACh on Engineered α4β2 nAChRs 
 
As in the previous experiments, ACh was used to test and confirm the uniformity of 
the engineered receptors population expressed in Xenopus laevis oocytes. 
Electrophysiological results of ACh on the engineered receptors, (43M)3(2)2 and 
(4)3(23M)2, indicated concentration response curves with potencies of, respectively 
7.5 µM (pEC50±SE=5.12±0.03), n = 6 and 150 µM (pEC50±SE = 3.79±0.03), n = 6 
(Figure 18). These results are similar to those of Harpsoe et al. [59]. Note the 
equivalence of ACh EC50 values on (4)3(2
3M
)2  to the low sensitivity component of  
wild type (4)3(2)2 suggesting the presence of three binding site for ACh as shown 
in Figure 12B . In fact, the results permit these engineered receptors to be used as 
standard mutants in this study. 
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Figure 18. Concentration-response relationship for ACh on (43M)3(2)2 and 
(4)3(2
3M
)2  nAChRs expressed in Xenopus laevis oocyte. 
Receptor populations were obtained by injecting wild-type and engineered mutants 
(43M with β2 and 4 with β23M into oocytes in 4:1 ratio to yield (43M)3(2)2 and 
(4)3(23M)2 nAChRs respectively. 3M denotes H142V, Q150F and T152L 
mutations on α4 and V136H, F144Q and L146T mutations on β2, respectively. 
Electrophysiology and data analysis were performed as explained in Figure 15. 
 
3.5 Choline Effects on Engineered α4β2 nAChRs 
 
Choline was tested on both engineered receptors ((4)3(23M)2 and (43M)3(2)2) 
and the results were in agreement with those found on wild type receptors, 
(4)3(23)2 and (4)3(2)2. On the (4)3(23M)2 receptor, which is a receptor with 
one native and two engineered 4-4 sites, choline potency was 0.3mM (EC50±SE = 
.07±0.00), n = 6) and the maximum response was 6% compared to the control 
maximum response (Figure 19A). To put the effect into perspective, the concentration 
response curves for choline on engineered receptors are plotted together with that of 
ACh (Figure 19B). This shows that, despite potencies in the same range (0.3 mM for 
choline and 0.15 mM for ACh), the efficacy of choline is significantly lower than that 
of ACh.  
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Figure 19. Concentration-response curve for choline and ACh on 43M)3(2)2 mutants 
receptors 
A: Concentration-response relationship for choline on (4)3(23M)2 (green) and (4
3M
)3(2)2 
(red) nAChRs expressed in Xenopus laevis oocyte. B: ACh concentration response curve on 
(4)3(23M)2  (blue) is compared to concentration-response relationship for  choline on 
(4)3(23M)2 (green) and (4
3M
)3(2)2 (red). Data analysis was performed as in Figure 15 
and regression results are summarised in Table 7 on page 71. 
 
These results resemble the efficacy and potency of choline on wild types (4)3(2)2. 
In contrast, choline had no effect on (43M)3(2)2 receptors indicating that an 4-4 
site is required for choline activity and choline efficacy on mutants did not increase as  
a result of the presence of additional 44 like binding sites. These effects, are also 
observed on current traces (Figure 20 A and B).   
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Figure 20. Sample current traces for an oocyte expressing the (4)3(2)2 mutants.  
Currents shown in A result from (4)3(23M)2 and those in B are from (43M)3(2)2.  
The first trace results from ACh 1mM (control) application followed by current traces of 
increasing concentration of choline. A 10 min. waiting period was included between each 
application. The holding potential was always -60mV. 
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The results show that choline does not interact with receptors that lack α4α4 binding 
site and may explain why it only interact with the native  (α4)3(β2)2 nAChRs, which 
theoretically means that this compound would have potentiating activity with other 
agonists able to bind at 4β2 binding sites of the same receptor. To investigate this 
hypothesis further, investigation on whether choline could potentiate the effect of 
ACh was explored by testing various concentrations of choline in the presence of a 
fixed concentration of ACh on the native (α4)3(β2)2 nAChRs, The results of these 
experiments are presented in the next section. 
3.6 Effect of Choline and ACh Co-application on (α4)3(β2)2 nAChRs 
 
In order to evaluate the effects of choline on ACh responses on (α4)3(β2)2 nAChRs, 
increasing concentrations of choline were mixed with a fixed concentration of 1µM 
ACh. In a subsequent experiment the effects at different concentrations (1 µM, 10 µM 
and 100 µM) of ACh were investigated, and data were plotted on a graph to construct 
concentration-response curves shown in Figure 21.   
 
 
 
 
 
 
 
 
 
Figure 21.  Concentration-response relationships for ACh and choline co-application on 
wild type (α4)3(β2)2 nAChRs expressed in Xenopus laevis oocytes.   
The cartoon next to the curve illustrates wild type (α4)3(β2)2 receptor. 
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The concentration-response curves as shown in Figure 21 (above) indicate that 
choline has a dual effect on (α4)3(β2)2 when it is co-applied with ACh. Low 
concentrations of choline result in an apparent potentiating effect with 1 µM and 10 
µM ACh, but these effects are reversed (inhibited) by choline in concentrations of 
1mM or higher. The observed potentiation effects are not high enough to conclude 
that they are a result of synergism of ACh and choline effects, and it cannot be 
concluded whether they are additive effects as potentiation did not appear at all 
concentrations. No potentiation was observed when choline was co-applied with 100 
µM ACh, but inhibition occurred with an IC50 value of 26mM (Figure 19C). This 
indicates that much higher concentration of choline are required to inhibit responses 
evoked by higher levels of ACh. These effects are clearly shown on individual 
concentration-response curve as well as the traces of current induced by each 
concentration of ACh co-applied with choline (Figure 22A-C).  
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Figure 22. Concentration-response relationships for ACh and choline co-application on 
(α4)3(β2)2 nAChRs expressed in Xenopus laevis oocytes.  
Increasing concentrations of choline were applied with three different fixed concentrations of 
ACh 1µM (A), 10 µM (B) and 100 µM (C).  Peak current amplitudes were normalised to the 
fixed saturating concentrations of 1µM, 10 µM and 100µM ACh respectively.  Regression 
results are shown in Table7 on page 71. Raw data of induced current are also shown (right) 
and the dotted line indicates the level of the maximum current induced by the control. 
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Similar choline effects to those observed in our results have been found in previous 
studies [133, 135]. In fact, both potentiating and inhibiting effects of choline on 4β4 
and 3β4 nAChRs and choline’s inhibiting effects on 4β2 nAChRs were reported 
(Table 6). Using the two-microelectrode voltage clamp technique, it was  shown that 
choline concentrations from 10 µM to 10mM potentiated responses evoked by 1 µM 
ACh on 4β4 receptors expressed in Xenopus oocytes, but ACh responses were 
inhibited by choline concentration higher than 10mM on the same receptors[135].  
 
In the same study, it was demonstrated that responses evoked by ACh 300 µM on 
4β4 were inhibited by choline with an IC50 of 0.87mM [135], which is 3 times 
higher than the IC50 required for inhibition of ACh 100 µM responses on (α4)3(β2)2 
in the present study. Although the above study was done on 4β4 nAChRs subtype, our 
results were generated using similar experimental methods and come to the same conclusion; 
namely, that choline has a dual activity and modulates the response of ACh on (α4)3(β2)2 
nAChRs. In addition both 4β2 and 4β4 nAChRs presented small differences in 
agonist affinities for a number of ligands tested; for example only 2 fold affinity 
differences for ACh [142]. 
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Table 6. Comparison of our Results with Previous Findings 
  Choline effects 
nAChR 
subtype 
Agonize  Potentiation Inhibtion 
Rat α4β2 
expressed in 
Xenopus oocytes 
(This Study) 
Weak partial 
agonist at 
(α4)3(β2)2, 
Imax: 4% of 
ACh Imax 
EC50=0.4 mM 
Concentrations of  
choline 10 µM to 300 µM 
potentiated  responses 
evoked by 1µM and 10 
µM ACh 
Concentrations of  choline 
>1mM inhibited  
responses evoked by 1µM 
or 10 µM ACh 
Rat 7 [80] 
 
 
Selective full 
agonist,  
 
  
EC50 = 1.6 mM 
Bovine 7 [134] 
 
 
A weak full 
agonist,  
 
  
EC50 = 0.43 mM. 
 
Rat 3β4 from 
hippocampal and 
dorsal striatal 
slices [133] 
 
ACh Potentiation by  
choline concentration < 3 
µM 
ACh Inhibition by  choline 
>3 µM,  IC50 of 15 µM 
Rat4β4 
expressed in 
Xenopus oocytes 
[135]
 
 Choline enhanced  
responses evoked by 1µM 
ACh 
300 µM  ACh was inhibited 
by   choline, IC50 = 
0.87mM 
Rat 4β2 from 
hippocampal and 
dorsal striatal 
slices [133] 
  
100 µM ACh was inhibited 
by 200 µM to 10 mM of  
choline,  IC50=372 µM   
 
Note. Choline behaved as an agonist or inhibitor on some nAChRs, and choline potentiated or 
inhibited ACh evoked responses on other subtypes. 
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A regulatory activity of choline on 3β4 and 4β2 nAChR-mediated glutamate 
excitatory postsynaptic currents (EPSCs) from neurons of rat hippocampal and dorsal 
striatal slices using whole-cell patch-clamp recordings was also demonstrated by 
Alkondon et al. [133]. In their study, concentrations of choline lower than 3 µM did 
enhance the magnitude of ACh-induced N-methyl-D-aspartate (NMDA) EPSCs, but 
higher concentration of choline inhibited NMDA EPSCs in CA1 stratum radiatum 
(SR) interneurons of rat hippocampal slices with an IC50 of 15 µM. Interestingly, 100 
µM ACh  on 4β2  nAChRs in CA1 SR interneuronswere inhibited by choline with 
an IC50 of 372 µM. This inhibition potency is 65 times higher than the inhibition 
potency observed in our results for 10 µM to 30 mM choline with 100 µM ACh on 
(α4)3(β2)2 expressed in Xenopus oocytes.  
The changes in responses evoked by 1 µM or 10 µM ACh on (α4)3(β2)2 appear to be 
significant with 300 µM choline. This observation led to the question of what could 
happen if choline is pre-incubated with receptors expressed in Xenopus oocytes 
followed by application of increasing concentrations of ACh. It was hypothesised that 
the prior incubation of choline may result in important potentiation of ACh response. 
This pre-incubation experiment was then designed and the findings are discussed in 
the following section. 
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3.7 Effect of ACh with Choline Pre-incubation on (α4)3(β2)2 nAChRs 
 
Choline effects on responses evoked by ACh on (α4)3(β2)2 nAChRs were evaluated by 
three minutes incubation of oocytes with 300µM choline ―at which concentration a 
maximum potentiation was observed when choline is coapplied with 1 µM ACh― 
and then followed by ACh application. Subsequent experimentation was conducted 
for increasing concentrations of ACh, and the concentration response relationship was 
constructed (Figure 20). Incubation of oocytes with choline resulted in a dramatic 
decrease of ACh efficacy and potency as compared to responses of ACh on oocytes 
without choline pre-incubation. The maximum response of ACh on (α4)3(β2)2 
receptors without choline pre-incubation fell from 120.5% to 52.4% when ACh was 
applied after choline pre-incubation, which is a decrease of nearly 70%. ACh potency 
(EC50) also steeply declined from 0.19mM (pEC50±SE = 3.71±0.14) to 2.3mM 
(pEC50±SE = 2.64±0.97), which is around 10 times less potent. It was also found that 
the potency of ACh on (α4)3(β2)2 nAChRs incubated with choline was six times less 
than the potency of choline on the same receptors. However, ACh efficacy on 
receptors incubated with choline remained higher (13 times) than the efficacy of 
choline.  
From these results, it is believed that prior incubation of choline with (α4)3(β2)2 
receptors has limited the full response of ACh. As opposed to choline and ACh co-
application, these two ligands are not applied at the same time. In fact, we believe that 
choline binds the receptors in the first instance and the later application of ACh 
interacts with remaining unoccupied receptors thus a downward shift of the maximal 
concentration-response curve occurs (Figure 23).  
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Inhibition of ACh responses by choline preincubation was also observed on α7 
nAChRs in a previous study. Using patch-clamp experiments on rat α7 from neurons 
of hypothalamic tuberomammillary slices, 2 to 5 minutes preincubation of 80 µM 
choline resulted in more than 60% efficacy reduction of 200 µM ACh [116].  
 
Figure 23. Concentration-response relationship for ACh and choline on (α4)3(β2)2 
nAChRs compared to curve for ACh recorded after pre-incubation with 300 µM 
choline.  
The cartoon next to the curve is an illustration of (α4)3(β2)2 receptors. Electrophysiology 
experiments and data analysis were performed as described in the legend to Figure. 15. Table 
7 on page 71 shows regression results. 
 
In this experiment, as shown on a sample of current traces (Figure 24), constant 
choline concentration of 300 µM was first applied and was run for 3 minutes (red 
line) before being stopped to let ACh solution (blue line) on the oocyte until the 
maximum response was achieved. A zoom-in on the 1mM ACh current trace (Figure 
24) shows that the response induced by 1mM ACh (610.9nA) on cells pre-incubated 
with 300 µM choline  is half of the maximum current induced by ACh (control) 
without choline pre-incubation (1271.88nA).  
  
69 
 
 
 
 
 
 
 
 
 
 
 
 
ACh 1mM ACh 1µM ACh 10µM ACh 30µM ACh 100µM ACh 300µM ACh 1mM ACh 3mM 
1500nA 
200sec 
ACh  
Choline 300µM 
 
Figure 24. Sample current traces for ACh applied on an oocyte expressing the wild types 
(α4)3(β2)2 nAChRs pre-incubation with 300 µM choline.  
The zoom-in on the 1mM ACh current trace is shown for close examination. Also note that 
1mM ACh was used as a control and the holding potential was -60mV.  
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This experiment shows an apparent washout of prior-incubated choline because the 
more an increased concentration of ACh is applied on receptors, the higher are the 
observed current-evoked responses. This may be explained by displacement of 
choline on receptors, which are then occupied by ACh.  
We believe that it would be of interest to maintain constant choline concentration 
along with application of increasing concentrations of ACh to evaluate the effects of 
constant choline concentration on ACh efficacy and potency. Nonetheless, results 
show that a receptor that has been exposed to choline becomes less sensitive and less 
responsive to ACh. The low response to ACh may be a result of either desensitisation 
of the receptors or competition binding between choline and ACh. These would have 
been distinguished by applying a much higher concentration of ACh on oocytes pre-
incubated with choline. If the receptors were desensitised by choline pre-incubation, 
their response to ACh is decreased and the full maximum response cannot be 
achieved by increasing concentration of ACh. Contrary to receptors desensitisation, in 
the case of choline and ACh competition the ACh full maximum response will be 
reproduced if a much higher concentration of ACh is applied on oocytes pre- 
incubated with choline. 
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Table 7. Regression Results for Different Concentration-Response Relationships  
  
                                                                      
Note. In this table, ligands ACh and choline were applied separately, in co-application or with 
choline pre-incubation on wild type or mutant (α4)3(β2)2  and (α4)2(β2)3 nAChRs. The 
regression results are pEC50 defined as the negative logarithmic value of EC50 and Imax 
defined as the maximum response produced by a ligand.  
                                                          
 
 
b
 pEC50: Negative logarithmic value of EC50 (pEC50= -LogEC50) 
 
c
  Imax: Maximum response produced by a ligand on the receptor 
d
 Pre-incubation: pre-treatment of the receptor with a ligand 
  
(α4)2(β2)3 (α4)3(β2)2 (α43M)3(β2)2 (α4)3(β23M)2 
  pEC50
b
  Imax
c
 pEC50 Imax pEC50 Imax pEC50 Imax 
ACh 5.5±0.08 1.04±0.03 3.9±0.09 1.05±0.05 5.12±0.03 1.02±0.02 3.79±0.03 1.03±0.02 
Choline - - 3.35±0.48 0.04±0.01 3.51±0.28 0.01±0.00 3.46±0.05 0.07±0.00 
Choline 
(increasing 
concentration) 
+ 1 µM ACh  
- - 4.06±0.73 1.11±0.06 - - - - 
Choline 
(increasing 
concentration)
+ 100 µM 
ACh  
- - 1.58±0.31 0.22±0.38 - - - - 
ACh 
(increasing 
concentration) 
+ 300 µM 
Choline pre-
incubation
d
 
- - 2.64±0.97 0.52±0.34 - - - - 
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Chapter 4 
Discussion 
 
 
The study of choline and nAChRs is of great interest because of their crucial role in 
physiological functions. It has been reported that choline is required for early CNS 
development [113]. It has been demonstrated that choline has a prominent role in 
cognitive, memory and neuroprotective functions [130]. These functions are mainly 
modulated by nAChRs and a number of conditions, such as smoking addiction and 
diseases including dementia and AD, are associated with dysfunction of nAChRs and 
an increase in brain choline levels [26, 47, 115, 143]. The nAChRs are pentameric ion 
channels situated on post synaptic neurons in cholinergic synapses where they 
mediate the response of ACh. These neurons have an absolute requirement of choline 
to synthesise ACh, and choline is reproduced from degradation of ACh by AChE to 
terminate ACh signaling[3]. Therefore, choline and ACh coexist in the synaptic cleft 
during ACh neurotransmission. Choline and ACh cohabitation in the synaptic cleft, 
together with the fact that the two molecules are structurally similar, justify the study  
of their individual and possible combined effects on the nAChRs.  
There are currently 12 different subunits (α4-α10 and β2-β4) that can be assembled in 
various combinations of five subunits to make an individual nAChR subtype, and 
each nAChR subtype is characterised by its pharmacological and physiological 
properties [2, 144]. Different compounds, including choline, have been tested on 
various nAChRs subtypes for the purpose of developing and designing new molecules 
that may translate into therapeutics.  
  
73 
 
The present study investigated the activity of choline on different stochiometries of rat 
α4β2 nAChRs, the most abundant and widely distributed nAChRs subtypes in rat as 
well as human brains. Choline effects were investigated on both wild and engineered 
α4β2 nAChRs expressed in Xenopus laevis.  
In this study, α4β2 nAChRs were expressed by altering the ratio of α4 and β2 subunit 
mRNA injected into X. laevis oocytes. The obtained receptors successfully responded 
to ACh with potency consistent with previous work [59]  and these predominantly 
consist of (α4)2(β2)3 containing nAChRs EC50= 3.4 µM (pEC50±SE=5.5±0.08) and 
(α4)3(β2)2 containing nAChRs EC50= 100 µM (pEC50±SE=5.5±0.08). 
 
Our findings revealed a stoichiometry-dependent activity of choline on wild type 
α4β2 nAChRs.  In fact, choline did not show any response on (α4)2(β2)3 
stoichiometry in which α4-α4 binding site is not present. In contrast, choline activated 
(α4)3(β2)2 stoichiometry in which at least an α4-α4 binding site is present.  At this 
receptor stoichiometry, choline showed a weak low affinity agonist effect with 
EC50=400 µM (pEC50±SE=3.35±0.48) and maximum efficacy four percent as 
compared to the control maximum response (ACh 1mM).  
We could not find previous similar studies that have tested choline on individual 
stochiometries of α4β2 nAChRs. However, our results can be indirectly compared to 
other available published data on choline activity on nAChRs. One study, for 
example, has found that choline does not activate α4β2 nAChRs on hippocampal 
neurons [80], but the stoichiometric composition of α4β2 nAChRs was not known. 
Our results may partly explain why choline effects were not previously observed on 
α4β2 nAChRs on hippocampal neurons. One reason may be that, as opposed to 
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Xenopus oocytes, choline was tested on neuron preparations that possibly bear 
different receptor subtypes and may require a much higher concentration of choline to 
induce an activity. Another possible explanation may lie in the α4β2 stochiometry 
composition in the neuron preparations, since we observed no effects of choline on 
(α4)2(β2)3 receptors. 
Our results also agree with other studies done in the past. For instance, an early study 
suggested that choline is a weak partial agonist of nAChRs receptors and has very low 
potency to account for the central nervous system effects [132]. More recent studies 
have suggested that choline behaves as a selective full agonist of α7 nAChRs and 
does activate and/or inhibit a number of other nAChRs. In fact, it has been 
demonstrated that choline is a full agonist of both rat and bovine α7 with EC50 of 
1.6mM and 0.43 mM respectively [80, 134]. Moreover, it has been shown that choline 
has dual effects on α3β4 and α4β4. It was reported that choline is a partial agonist for 
α3β4 nAChRs on PC12 cells but is a voltage dependent blocker of α3β4 with an IC50 
of 0.97mM [134].  
In this study, we also tested choline on engineered α4β2 nAChRs, which allowed us 
to identify differences in choline sensitivity on α4α4 and α4β2 binding sites. In this 
case, we showed that choline activated receptors that contained one native α4α4 and 
two engineered α4α4 binding sites, (4)3(23M)2 although the introduction of more 
α4α4 binding sites did not increase the maximum efficacy. In contrast, we did not 
observe effects on receptors that contained two native α4β2 and one engineered α4β2 
binding sites, (43M)3(2)2. These differences in choline sensitivity on engineered 
receptors may be explained by the structural composition and properties of α4α4 and 
α4β2 binding sites. In fact, three residues (His142, Gln150, and Thr152) on α4 and 
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three residues on β2 (Val136, Phe144, and Leu146) differentiate between α4α4 and 
α4β2 binding sites [59]. The residues on α4 bear a number of nitrogen and oxygen 
atoms able to make hydrogen bonds, thus the α4α4 binding site may prefer a 
hydrophilic molecule like choline.  In contrast, the three residues on β2 tend to be 
more hydrophobic due to lipophilic residues facing the binding site, which may result 
in less favourable binding of choline. If these explanations are correct, they may also 
clarify why choline did not activate the wild type (α4)2(β2)3 receptors, which only 
contain two α4β2 binding sites. 
In our investigation, choline and ACh co-application showed that, depending on 
concentration, choline potentiates or inhibits responses evoked by ACh on (α4)3(β2)2. 
The concentration of choline, ranging from 10 µM to 300 µM, potentiated responses 
evoked by 1 µM and 10µM ACh, but those responses were inhibited by choline 
concentrations above 1mM. In fact, in physiological conditions choline concentrations 
range between 10–20 µM [114, 115], and these are relatively similar to the 
concentrations that potentiated ACh evoked responses. Furthermore, in pathological 
conditions, choline levels can reach 100 µM, which is still in range of the 
concentrations of choline that showed potentiating effects of ACh responses. The fact 
that the effects we observed in Xenopus oocytes take place at concentrations that are 
physiologically relevant suggests an important physiological role for choline. This 
role is to maintain ACh-mediated neurotransmission in normal conditions by 
enhancing the low responses of ACh and reducing overstimulation due to high 
concentration of ACh. This supports the hypothesis that choline may have other 
physiological roles beyond that of being a precursor and metabolite of ACh. 
  
76 
 
Moreover, similar observations of choline regulating ACh activity on α4β4 [135] and 
α3β4 [133] have been reported (see Table 4).  
We also showed that a prior application of choline on (α4)3(β2)2 nAChRs results in a 
dramatic reduction of ACh evoked responses. This particular observation may be 
explained by the structural properties of binding sites in the (α4)3(β2)2 receptors.  
Choline, which is more lipophilic than ACh, may more likely interact with the α4α4 
binding site. It is also known that, in order to observe a full ACh response on 
(α4)3(β2)2, it is necessary for ACh to bind to both the α4α4 and α4β2 binding sites 
[59]. Consequently if choline is pre-incubated with the receptors, it will partly prevent 
ACh from binding on the α4α4 binding site, resulting in decreased efficacy.    
Overall, for the first time choline effects have been demonstrated on each of the α4β2 
stochiometries and we have proposed that choline has a selective activity on wild type 
receptor stochiometry bearing at least one α4α4 binding site. This has been also 
confirmed on mutant receptors. Moreover, our study revealed that choline (depending 
on concentration) enhances or inhibits ACh effects on (α4)3(β2)2 receptors. These 
results reinforce dual activity of choline on some nAChRs reported in previous 
studies.
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Chapter 5 
Conclusion 
 
Nicotinic acetylcholine receptors in the brain constitute an important group of 
receptors in the cholinergic system and contribute to various CNS functions, including 
learning and memory, attention, and emotional processing. A large number of 
neuronal disorders such as Alzheimer’s, Parkinson, schizophrenia and addiction are 
related to nAChRs dysfunction.  The present project has focused on α4β2, the most 
abundant nAChRs subtype and one that is widely distributed in the mammalian brain. 
The main goal was to pharmacologically evaluate the effects of choline on α4β2 
nAChRs expressed in Xenopus laevis oocytes using the two-electrode voltage clamp 
electrophysiology technique. This study, in contrast to previous research, has 
investigated the effects of choline on different stoichiometries of wild types α4β2 
nAChRs, (α4)3(β2)2 and (α4)2(β2)3.  
 
It was demonstrated that choline activates (α4)3(β2)2 stoichiometry, and no visible 
choline response on (α4)2(β2)3stochiometry, which has never been found before. 
Further investigation of choline effects on engineered α4β2 receptors has confirmed 
that choline preferably activates receptors containing at least one α4α4 interface, 
which is only present in the (α4)3(β2)2 stoichiometry. We recommend further binding 
and structural studies of choline on α4β2nAChRs to explore the reason behind 
selective stochiometry activation.  
 
The potentiatiation and inhibition of ACh evoked responses on (α4)3(β2)2 receptors 
by, respectively, low and high concentrations of choline suggest that choline may 
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have a role in maintaining ACh neurotransmission in normal range. Our results 
provide additional support for the hypothesis that choline has a relevant physiological 
role other than that of simply being a precursor and metabolite of ACh  
 
The prior incubation of (α4)3(β2)2 nAChRs with choline has enormous effects on 
ACh induced currents. There is a strong belief that choline competes with ACh on 
α4α4 binding site, which may consequently lead to decreased (α4)3(β2)2 sensitivity 
and responsiveness of ACh application. However, this needs to be investigated in 
further studies. 
 
The findings from this study contribute to the understanding of the function of 
nAChRs, particularly α4β2 subtype. The observed effects of choline on α4β2 
receptors could lead future investigation of nAChRs in the purpose of designing novel  
ligands that may translate into therapeutics.
  
79 
 
References 
 
1. Woolf, N.J., Cholinergic systems in mammalian brain and spinal cord. 
Progress in Neurobinlogy, 1991. 37: p. 475-524. 
2. Albuquerque, E.X., et al., Mammalian Nicotinic Acetylcholine Receptors: 
From Structure to Function. Physiol Review, 2009. 89: p. 73-120. 
3. Blusztajn, J.K. and R.J. Wurtman, Choline and Cholinergic neurons. Science, 
New Series, 1983. 221(4611): p. 614-620. 
4. Prado, M.A.M., et al., Regulation of acetylcholine synthesis and storage. 
Neurochemistry International 2002. 41: p. 291-299. 
5. Millar, N.S., Assembly and subunit diversity of nicotinic acetylcholine 
receptors. Biochemical Society Transactions, 2003. 31(4). 
6. Wonnacott, S., Presynaptic nicotinic ACh receptors. Trends Neurosci, 1997. 
20: p. 92-98. 
7. Wecker, L. and C.Q. Rogers, Phosphorylation sites within [alpha]4 subunits 
of [alpha]4[beta]2 neuronal nicotinic receptors: A comparison of substrate 
specificities for cAMP-dependent protein kinase (PKA) and protein kinase C 
(PKC). Neurochemical Research, 2003. 28(3/4): p. 431-436. 
8. Gotti, C. and F. Clementi, Neuronal nicotinic receptors: from structure to 
pathology. Progress in Neurobiology, 2004. 74(6): p. 363-396. 
9. S., L., S. Mexal, and S. Freedman, Smoking, Genetics and Schizophrenia: 
Evidence for Self Medication. J Dual Diagn, 2007. 3: p. 43-59. 
10. McClernon, F.J. and S.H. Kollins, ADHD and smoking: from genes to brain to 
behavior. Ann N Y Acad Sci, 2008. 1141: p. 131-47. 
11. Rezvani, A.H. and E.D. Levin, Cognitive effects of nicotine. Biol Psychiatry, 
2001. 49(3): p. 258-67. 
12. Piciotto, C., et al., Acetylcholine receptors containing the beta2 subunit are 
involved in the reinforcing properties of nicotine. Nature, 1998. 391  
13. Kumari, V., et al., Cognitive effects of nicotine in humans: an fMRI study. 
NeuroImage, 2003. 19(3): p. 1002-1013. 
14. Owen, A.M., et al., N-back working memory paradigm: a meta-analysis of 
normative functional neuroimaging studies. Human Brain Mapping, 2005. 
25(1): p. 46-59. 
15. Marubio, L.M. and R. Paylor, Impaired passive avoidance learning in mice 
lacking central neuronal nicotinic acetylcholine receptors. Neuroscience, 
2004. 129(3): p. 575-82. 
16. Levin, E.D., Nicotinic receptor subtypes and cognitive function. J Neurobiol, 
2002. 53(4): p. 633-40. 
17. Thienel, R., et al., Nicotinic antagonist effects on functional attention 
networks. Int J Neuropsychopharmacol, 2009. 12(10): p. 1295-305. 
18. Ellis, J.R., et al., Relationship between nicotinic receptors and cognitive 
function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. 
Neurobiol Learn Mem, 2008. 90(2): p. 404-12. 
19. Roni, M.A. and S. Rahman, Neuronal nicotinic receptor antagonist reduces 
anxiety-like behavior in mice. Neurosci Lett, 2011. 504(3): p. 237-41. 
  
80 
 
20. Freedman, R., et al., Evidence in postmortem brain tissue for decreased 
numbers of hippocampal nicotinic receptors in schizophrenia. Biological 
Psychiatry, 1995. 38(1): p. 22-33. 
21. Levin , E.D. and A.H. Rezvani, Development of nicotinic drug therapy for 
cognitive disorders. European Journal of pharmacology, 2000. 393: p. 141–
146. 
22. Okada, H., et al., Alterations in α4β2 nicotinic receptors in cognitive decline 
in Alzheimer's aetiopathology. Brain, 2013. 136(10): p. 3004-3017. 
23. Meyer, P.M., et al., Reduced a4b2–Nicotinic Acetylcholine Receptorbinding 
and its relationship to mild cognitive and depressive symptoms in parkinson 
disease. Arch Gen Psychiatry, 2009. 66(8): p. 866-877. 
24. Selkoe, D.J. and P.J. Lansbury, Basic Neurochemistry Molecular, Cellular and 
Medical Aspects 6ed. Alzheimer's Disease Is the Most Common 
Neurodegenerative Disorder, ed. A.B. Siegel GJ, Albers RW, et al. 1999, 
Philadelphia: American Society for Neurochemistry. 
25. Duthey, B., Background Paper 6.11 Alzheimer Disease and other Dementias, 
in Priority Medicines for Europe and the World Project "A Public Health 
Approach to Innovation". 2013, WHO. 
26. Nordberg, A., Nicotinic Receptor Abnormalities of Alzheimer’s disease : 
Therapeutic Implications. Biological psychiatry, 2001. 49: p. 200-210. 
27. Guan, Z.-Z., et al., Decreased Protein Levels of Nicotinic Receptor Subunits in 
the Hippocampus and Temporal Cortex of Patients with Alzheimer’s Disease. 
Journal of Neurochemistry, 2000. 74: p. 237-243. 
28. Sugaya, K., E. Giacobini, and V.A. Chiappinelli, Nicotinic acetylcholine 
receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J 
Neurosci Res, 1990. 27(3): p. 349-59. 
29. WHO, Global Health Risks: Mortality and burden of disease attributable to 
selected major risks. 2009: World Health Organization, 20 Avenue Appia, 
1211 Geneva 27, Switzerland. 
30. Balfour, D.J.K., Nicotine and the tobacco smoking habit. 1st ed. International 
encyclopedia of pharmacology and therapeutics. 1984, Oxford ; New York: 
Pergamon Press. xi, 221 p. 
31. Le Foll, B., et al., Baseline expression of alpha4beta2 nicotinic acetylcholine 
receptors predicts motivation to self-administer nicotine. Biol Psychiatry, 
2009. 65(8): p. 714-6. 
32. Coe, J.W., et al., Varenicline: An alpha4beta2 Nicotinic Receptor Partial 
Agonist for Smoking Cessation. Medicinal Chemistry, 2005. 48: p. 3474-3477. 
33. Biederman, J., et al., Predictors of persistent ADHD: an 11-year follow-up 
study. J Psychiatr Res, 2011. 45(2): p. 150-5. 
34. Searight, H.R., J.M. Burke, and F. Rottnek, Adult ADHD: evaluation and 
treatment in family medicine. Am Fam Physician, 2000. 62(9): p. 2077-86, 
2091-2. 
35. Kollins, S.H., F.J. McClernon, and B.F. Fuemmeler, Association Between 
Smoking and Attention-Deficit/Hyperactivity Disorder Symptoms in a 
Population-Based Sample of Young Adults. Arch Gen Psychiatry, 2005. 62: p. 
1142-1147. 
36. Bain, E.E., et al., A randomized, double-blind, placebo-controlled phase 2 
study of alpha4beta2 agonist ABT-894 in adults with ADHD. 
Neuropsychopharmacology, 2013. 38(3): p. 405-13. 
  
81 
 
37. Helzer, J.E., et al., Smoking, smoking cessation, and major depression. JAMA, 
1990. 264: p. 1546-1549. 
38. H., G.A., S. Fay, and L.S. Covey, Major depression following smoking 
cessation. The American Journal of Psychiatry, 1997. 154(2): p. 263. 
39. Johnson, E.O. and N. Breslau, Predicting Smoking Cessation and Major 
depression in nicotine dependent smokers. American Journal of Public Health, 
2000. 90(7). 
40. Lukas, R.J., R. Gruener, and R. Reitstetter, Dependence of Nicotinic 
Acetylcholine Receptor Recovery from Desensitization on the Duration of 
Agonist Exposure. The Journal of pharmacology and experimental 
therapeutics, 1999. 289(2): p. 656. 
41. Breslau, N., Psychiatric comorbidity of smoking and nicotine dependence. 
Behavior Genetics, 1995. 25(2). 
42. Kaniakova, M., et al., Dual effect of lobeline on alpha4beta2 rat neuronal 
nicotinic receptors. Eur J Pharmacol, 2011. 658(2-3): p. 108-13. 
43. Roni, M.A. and S. Rahman, Antidepressant-like effects of lobeline in mice: 
behavioral, neurochemical, and neuroendocrine evidence. Prog 
Neuropsychopharmacol Biol Psychiatry, 2013. 41: p. 44-51. 
44. Goff, D.C., D.C. Henderson, and E. Amico, Cigarette smoking in 
schizophrenia:relationship to psychopathology and medication side effects. 
The American journal of psychiatry, 1992. 149(9): p. 1189-1194. 
45. Duranya, N., et al., Human post-mortem striatal α4β2 nicotinic acetylcholine 
receptor density in schizophrenia and Parkinson's syndrome. Neuroscience 
Letters, 2000. 287(2): p. 109-112. 
46. Perez, X.A., et al., alpha6beta2* and alpha4beta2* nicotinic receptors both 
regulate dopamine signaling with increased nigrostriatal damage: relevance 
to Parkinson's disease. Mol Pharmacol, 2010. 78(5): p. 971-80. 
47. Gotti, C., D. Fornasari, and F. Clementi, Human Neuronal Nicotinic 
Receptors. Progress in Neurobiology, 1997. 53: p. 199-237. 
48. Gotti, C., M. Zoli, and F. Clementi, Brain nicotinic acetylcholine receptors: 
native subtypes and their relevance. Trends in Pharmacological Sciences, 
2006. 27(9): p. 482-491. 
49. Galzi, J.L. and J.P. Changeux, Neuronal Nicotinic Receptors Molecular 
organization and Regulations. Neuropharmacology, 1995. 34(6): p. 563-582. 
50. Jensen, A.A., et al., Neuronal Nicotinic Acetylcholine Receptors: Structural 
Revelations, Target Identification and Therapeutic Inspirations. Journal of 
Medicinal Chemistry, 2005. 48(15). 
51. Buccafusco, J.J., Neuronal Nicotinic Receptor Subtypes: Defining therapeutic 
targets. Molecular interventions, 2004. 4(5). 
52. Unwin, N., Refined structure of the nicotinic acetylcholine receptor at 4A 
resolution. Journal of Molecular Biology, 2005. 346(4): p. 967-89. 
53. Unwin, N., Acetylcholine receptor channel imaged in the open state. Nature, 
1995. 373(6509): p. 37. 
54. Miyazawa, A., Y. Fujiyoshi, and N. Unwin, Structure and gating mechanism 
of the acetylcholine receptor pore. Nature, 2003. 423(6943): p. 949. 
55. Gotti, C., et al., Heterogeneity and complexity of native brain nicotinic 
receptors. Biochem Pharmacol, 2007. 74(8): p. 1102-11. 
56. Nelson, M.E., et al., Alternate Stoichiometries of α4β2 Nicotinic Acetylcholine 
Receptors. Molecular Pharmacology, 2003. 63: p. 332-341. 
  
82 
 
57. Rogers, S.W., et al., A subtype of nicotinic cholinergic receptor in rat brain is 
composed of alpha 4 and beta 2 subunits and is up-regulated by chronic 
nicotine treatment. Molecular pharmacology, 1992. 41(1): p. 31. 
58. Nguyen, H.N., B.A. Rasmussen, and D.C. Perry, Subtype-selective up-
regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain 
demonstrated by receptor autoradiography. J Pharmacol Exp Ther, 2003. 
307(3): p. 1090-7. 
59. Harpsoe, K., et al., Unraveling the High- and Low-Sensitivity Agonist 
Responses of Nicotinic Acetylcholine Receptors. Journal of Neuroscience, 
2011. 31(30): p. 10759-10766. 
60. Nashmi, R. and H.A. Lester, CNS Localization of Neuronal Nicotinic 
Receptors. Journal of Molecular Neuroscience, 2006. 30: p. 181-184. 
61. Ahring, P.K., et al., Engineered alpha4beta2 nicotinic acetylcholine receptors 
as models for measuring agonist binding and effect at the orthosteric low-
affinity alpha4-alpha4 interface. Neuropharmacology, 2015. 92: p. 135-45. 
62. Brejc, K., et al., Crystal structure of acetylcholine binding protein reveals 
ligand binding domain of nicotinic receptors. Nature 2001. 411( ): p. 269-276. 
63. Cashin, A.L., et al., Using physical chemistry to differentiate nicotinic from 
cholinergic agonists at the nicotinic acetylcholine receptors. American 
Chemical Society, 2005(127): p. 350-356. 
64. Paterson, D. and A. Nordberg, Neuronal nicotinic receptors in the human 
brain. Progress in Neurobiology, 2000. 61: p. 75-111. 
65. Dennis, M., et al., Amino Acids of the Torpedo marmorata Acetylcholine 
Receptor alpha Subunit Labeled by a Photoaffinity Ligand for the 
Acetylcholine Binding Site. Biochemistry, 1988. 27(7): p. 2346-2357. 
66. Smit, A.B., et al., A glia-derived acetylcholine-binding protein that modulates 
synaptic transmission. Nature, 2001. 411: p. 261-268. 
67. Olsen, J.A., et al., Molecular Recognition of the Neurotransmitter 
Acetylcholine by an Acetylcholine Binding Protein Reveals Determinants of 
Binding to Nicotinic Acetylcholine Receptors. PLOS ONE, 2014. 9(3). 
68. Mazzaferro, S., et al., Non-equivalent ligand selectivity of agonist sites in 
(alpha4beta2)2alpha4 nicotinic acetylcholine receptors: a key determinant of 
agonist efficacy. J Biol Chem, 2014. 289(31): p. 21795-806. 
69. Harkins, A.B. and A.P. Fox, Activation of Nicotinic Acetylcholine Receptors 
Augments Calcium Channel-mediated Exocytosis in Rat Pheochromocytoma 
(PC12) Cells. Journal of General Physiology, 1998. 111: p. 257–269. 
70. Perez-Alvarez, A. and A. Albillos, Key role of the nicotinic receptor in 
neurotransmitter exocytosis in human chromaffin cells. J Neurochem, 2007. 
103(6): p. 2281-90. 
71. McKay, B.E., A.N. Placzek, and J.A. Dani, Regulation of synaptic 
transmission and plasticity by neuronal nicotinic acetylcholine receptors. 
Biochem Pharmacol, 2007. 74(8): p. 1120-33. 
72. Dajas-Bailador, F. and S. Wonnacott, Nicotinic acetylcholine receptors and 
the regulation of neuronal signalling. Trends Pharmacol Sci, 2004. 25(6): p. 
317-24. 
73. Wilson, G. and A. Karlin, Acetylcholine receptor channel structure in the 
resting, open, and desensitized states probed with the substituted-cysteine-
accessibility method. Proc Natl Acad Sci U S A, 2001. 98(3): p. 1241-8. 
  
83 
 
74. Paradiso, K.G. and J.H. Steinbach, Nicotine is highly effective at producing 
desensitization of rat alpha4beta2 neuronal nicotinic receptors. J Physiol, 
2003. 553(Pt 3): p. 857-71. 
75. Changeux, J.-P., A. Devillers-Thiéry, and P. Chemouilli, Acetylcholine: An 
allosteric protein. Science, New Series, 1984. 225(4668): p. 1335-1345. 
76. Wonnacott, S., N. Sidhpura, and D.J. Balfour, Nicotine: from molecular 
mechanisms to behaviour. Curr Opin Pharmacol, 2005. 5(1): p. 53-9. 
77. Tansey, E.M., Henry Dale and the discovery of acetylcholine. C R Biol, 2006. 
329(5-6): p. 419-25. 
78. Gotti, C., et al., Brain Neuronal Nicotinic Receptors as New Targets for Drug 
Discovery agonists and antagonists. Current Pharmaceutical Design, 2006. 12: 
p. 407-428. 
79. Moroni, M., et al., α4β2 Nicotinic Receptors with High and Low Acetylcholine 
Sensitivity: Pharmacology, Stoichiometry, and Sensitivity to Long-Term 
Exposure to Nicotine. Molecular Pharmacology, 2006. 70(2): p. 755-768. 
80. Alkondon , M., et al., Choline is a Selective Agonist of α7 Nicotinic 
Acetylcholine Receptors in the Rat Brain Neurons. European Journal of 
Neuroscience, 1997. 9: p. 2734-2742. 
81. Lomazzo, E., et al., Effects of chronic nicotine on heteromeric neuronal 
nicotinic receptors in rat primary cultured neurons. J Neurochem, 2011. 
119(1): p. 153-64. 
82. Celie, P.H.N., et al., Nicotine and Carbamylcholine Binding to Nicotinic 
Acetylcholine Receptors as Studied in AChBP Crystal Structures. Neuron, 
2004. 41: p. 907-914. 
83. Peng, X., et al., Nicotine-induced increase in neuronal nicotinic receptors 
results from a decrease in the rate of receptor turnover. Molecular 
pharmacology, 1994. 46(3): p. 523-530. 
84. Brody, A.L., et al., Treatment for tobacco dependence: effect on brain 
nicotinic acetylcholine receptor density. Neuropsychopharmacology, 2013. 
38(8): p. 1548-56. 
85. Mukhin, A.G., et al., Greater nicotinic acetylcholine receptor density in 
smokers than in nonsmokers: a PET study with 2-18F-FA-85380. J Nucl Med, 
2008. 49(10): p. 1628-35. 
86. Govind, A.P., H. Walsh, and W.N. Green, Nicotine-induced upregulation of 
native neuronal nicotinic receptors is caused by multiple mechanisms. J 
Neurosci, 2012. 32(6): p. 2227-38. 
87. Pidoplichko, V.I., et al., Nicotinic cholinergic synaptic mechanisms in the 
ventral tegmental area contribute to nicotine addiction. Learn Mem, 2004. 
11(1): p. 60-9. 
88. Djordjevic, M.V., S.D. Stellman, and E. Zang, Doses of Nicotine and Lung 
Carcinogens Delivered to Cigarette Smokers. Journal of the National Cancer 
Institute, 2000. 92(2): p. 106-111. 
89. Bergen, A.W. and N. Caporaso, Cigarette Smoking. Journal of the National 
Cancer Institute, 1999. 91(16): p. 1365–1375. 
90. Arneric, S.P., et al., (S)-3-Methyl-5-(1-Methyl-2-Pyrrolidinyl) Isoxazole (ABT 
418): A Novel Cholinergic Ligand with Cognition-Enhancing and Anxiolytic 
Activities: In Vitro Characterization. Journal of Pharmacology and 
Experimental Therapeutics, 1994. 270(1): p. 310 - 318. 
  
84 
 
91. Rueter, L.E., et al., ABT-089: Pharmacological Properties of a Neuronal 
Nicotinic Acetylcholine Receptor Agonist for the Potential Treatment of 
Cognitive Disorders. CNS Drug Reviews, 2004. 10(2): p. 167-182. 
92. Apostol, G., et al., Efficacy and safety of the novel alpha(4)beta(2) neuronal 
nicotinic receptor partial agonist ABT-089 in adults with attention-
deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled 
crossover study. Psychopharmacology (Berl), 2012. 219(3): p. 715-25. 
93. Rowland, N.E., et al., Nicotine analog inhibition of nicotine self-
administration in rats. Psychopharmacology (Berl), 2008. 199(4): p. 605-13. 
94. Levin, E.D. and A.H. Rezvani, Nicotinic interactions with antipsychotic drugs, 
models of schizophrenia and impacts on cognitive function. Biochem 
Pharmacol, 2007. 74(8): p. 1182-91. 
95. Levin, E.D., M. Cauley, and A.H. Rezvani, Improvement of attentional 
function with antagonism of nicotinic receptors in female rats. Eur J 
Pharmacol, 2013. 702(1-3): p. 269-74. 
96. Young, J.M., et al., Mecamylamine: New Therapeutic Uses and Toxicity/Risk 
profile. Clinical therapeutics, 2001. 23(4). 
97. Rosea, J.E., F.M. Behm, and E.C. Westmana, Acute effects of nicotine and 
mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib 
smoking. Pharmacology, Biochemistry and Behavior, 2001. 68: p. 187±197. 
98. Shytle, R.D., et al., Neuronal nicotinic receptor inhibition for treating mood 
disorders: preliminary controlled evidence with mecamylamine. Depress 
Anxiety, 2002. 16(3): p. 89-92. 
99. Cannady, R., et al., Nicotinic antagonist effects in the mediodorsal thalamic 
nucleus: regional heterogeneity of nicotinic receptor involvement in cognitive 
function. Biochem Pharmacol, 2009. 78(7): p. 788-94. 
100. Levin, E.D. and D.P. Caldwell, Low-dose mecamylamine improves learning of 
rats in the radial-arm maze repeated acquisition procedure. Neurobiol Learn 
Mem, 2006. 86(1): p. 117-22. 
101. Cheeta, S., S. Tucci, and S.E. File, Antagonism of the anxiolytic effect of 
nicotine in the dorsal raphe´ nucleus by di-hydro-beta-erythroidine. 
Pharmacology, Biochemistry and Behavior 2001. 70: p. 491-496. 
102. Jepsen, T.H., et al., Synthesis and Pharmacological Evaluation of DHbetaE 
Analogues as Neuronal Nicotinic Acetylcholine Receptor Antagonists. ACS 
Med Chem Lett, 2014. 5(7): p. 766-70. 
103. Setti-Perdiga, P., et al., Erythrina mulungu Alkaloids Are Potent Inhibitors of 
Neuronal Nicotinic Receptor Currents in Mammalian Cells. PLOS ONE, 
2013. 8(12). 
104. Maelicke , A., et al., Allosterically potentiating ligands of nicotinic receptors 
as a treatment strategy for Alzheimer's disease. Beha6ioural Brain Research, 
2000. 113: p. 199-206. 
105. Maelicke, A., et al., Allosteric Sensitization of Nicotinic Receptors by 
Galantamine a new Treatment Strategy for Alzheimer's disease. Biological 
Psychiatry, 2001. 49: p. 279-288. 
106. Weltzin, M.M. and M.K. Schulte, Pharmacological Characterization of the 
Allosteric Modulator Desformylflustrabromine and Its Interaction with  4 2 
Neuronal Nicotinic Acetylcholine Receptor Orthosteric Ligands. Journal of 
Pharmacology and Experimental Therapeutics, 2010. 334(3): p. 917-926. 
  
85 
 
107. Williams, D.K., J. Wang, and R.L. Papke, Positive allosteric modulators as an 
approach to nicotinic acetylcholine receptor-targeted therapeutics: 
Advantages and limitations. Biochemical Pharmacology, 2011. 82(8): p. 915-
930. 
108. Olsen, J.A., et al., Two distinct allosteric binding sites at alpha4beta2 
nicotinic acetylcholine receptors revealed by NS206 and NS9283 give unique 
insights to binding activity-associated linkage at Cys-loop receptors. J Biol 
Chem, 2013. 288(50): p. 35997-6006. 
109. Liu, X., Positive allosteric modulation of alpha4beta2 nicotinic acetylcholine 
receptors as a new approach to smoking reduction: evidence from a rat model 
of nicotine self-administration. Psychopharmacology (Berl), 2013. 230(2): p. 
203-13. 
110. Pandya, A. and J.L. Yakel, Allosteric modulators of the α4β2 subtype of 
neuronal nicotinic acetylcholine receptors. Biochemical Pharmacology, 2011. 
82(8): p. 952-958. 
111. Broad, L.M., et al., Identification and pharmacological profile of a new class 
of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp 
Ther, 2006. 318(3): p. 1108-17. 
112. Buchman, A.L., The addition of choline to parenteral nutrition. 
Gastroenterology, 2009. 137(5 Suppl): p. S119-28. 
113. Zeisel, S.H. and J.K. Blusztajn, Choline and human nutrition. Annual review 
of nutrition, 1994. 14(1): p. 269 - 296  
114. Farooqui, A.A. and L.A. Horrocks, Excitatory amino acid receptors, neural 
membrane phospholipid metabolism and neurological disorders. Bruin 
Research Reviews, 1991(16): p. 171-191. 
115. Jope, R.S. and X. Gu, Seizures increase acetylcholine and choline 
concentrations in rat brain regions. Neurochemical research, 1991. 16: p. 
1219-1226. 
116. Uteshev, V.V., E.M. Meyer, and R.L. Papke, Regulation of neuronal function 
by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors. J 
Neurophysiol, 2003. 89(4): p. 1797-806. 
117. Dechent, P., P.J.W. Pouwels, and J. Frahm, Oral Choline Does Not Alter 
Brain Metabolites Concentrations in Human Brain. Biological Psychiatry, 
1999. 46: p. 406-411. 
118. Wurtman, R.J., M. Cansev, and I.H. Ulus, Choline and its products 
acetylcholine and phosphatidylcholine.pdf>, in Neural Lipids, Handbook of 
Neurochemistry and Molecular Neurobiology, L. A, Editor. 2009. p. 443-501. 
119. Misawa, H., et al., Distribution of the high-affinity choline transporter in the 
central nervous system of the rat. Neuroscience, 2001. 105(1): p. 87-98. 
120. Ueland, P.M., Choline and betaine in health and disease. J Inherit Metab Dis, 
2011. 34(1): p. 3-15. 
121. Katz-Brull, R., A.R. Koudinov, and H. Degani, Choline in the aging brain. 
Brain Research 2002. 951 p. 158-165. 
122. Lockman, P.R. and D.D. Allen, The transport of choline. Drug Dev Ind 
Pharm, 2002. 28(7): p. 749-71. 
123. McMahon, K.E. and P.M. Farrell, Measurement of free choline concentrations 
in maternal and neonatal blood by micropyrolysis gas chromatography. 
Clinica Chimica Acta, 1985. 149: p. l-12. 
  
86 
 
124. Zeisel, S.H., M.F. Epstein, and R.J. Wurtman, Elevated choline concentration 
in neonatal plasma. Life Sciences, 1980. 26: p. 1827-1831. 
125. Ilcol, Y.O., et al., Choline status in newborns, infants, children, breast-feeding 
women, breast-fed infants and human breast milk. J Nutr Biochem, 2005. 
16(8): p. 489-99. 
126. Meck, W.H. and C.L. Williams, Metabolic imprinting of choline by its 
availability during gestation: implications for memory and attentional 
processing across the lifespan. Neuroscience & Biobehavioral Reviews, 2003. 
27(4): p. 385-399. 
127. Buhusi, C.V., J.A. Lamoureux, and W.H. Meck, Prenatal choline 
supplementation increases sensitivity to contextual processing of temporal 
information. Brain Res, 2008. 1237: p. 204-13. 
128. Wong-Goodrich, S.J., et al., Prenatal choline supplementation attenuates 
neuropathological response to status epilepticus in the adult rat hippocampus. 
Neurobiol Dis, 2008. 30(2): p. 255-69. 
129. Yang, Y., et al., Protective Effects of Prenatal Choline Supplementation on 
Seizure Induced Memory Impairment. The Journal of Neuroscience, 2000. 20: 
p. 1-6. 
130. Meck, W.H., et al., Developmental periods of choline sensitivity provide an 
ontogenetic mechanism for regulating memory capacity and age-related 
dementia. Front Integr Neurosci, 2007. 1: p. 7. 
131. Wong-Goodrich, S.J., et al., Spatial memory and hippocampal plasticity are 
differentially sensitive to the availability of choline in adulthood as a function 
of choline supply in utero. Brain Res, 2008. 1237: p. 153-66. 
132. Ulus, I.H., et al., Choline as an agonist: Determination of its agonistic potency 
on cholinergic receptors. Biochemkal Pharmacology, 1988. 37(14): p. 2747-
2755. 
133. Alkondon, M. and E.X. Albuquerque, Subtype-specific inhibition of nicotinic 
acetylcholine receptors by choline: a regulatory pathway. J Pharmacol Exp 
Ther, 2006. 318(1): p. 268-75. 
134. Gonzalez-Rubio, J.M., et al., Activation and blockade by choline of bovine 
alpha7 and alpha3beta4 nicotinic receptors expressed in oocytes. Eur J 
Pharmacol, 2006. 535(1-3): p. 53-60. 
135. Zwart, R. and H.P.M. Vijverberg, Potentiation and inhibition of neuronal 
α4β4 nicotinic acetylcholine receptors by choline. 2000. 393: p. 209–214. 
136. Fischer, V., et al., Choline-mediated modulation of hippocampal sharp wave-
ripple complexes in vitro. J Neurochem, 2014. 129(5): p. 792-805. 
137. Gahring, L.C., G.A. Vasquez-Opazo, and S.W. Rogers, Choline promotes 
nicotinic receptor alpha4 + beta2 up-regulation. J Biol Chem, 2010. 285(26): 
p. 19793-801. 
138. Dale, J., Molecular genetics of bacteria. 3 ed. 1998, New York Chichester ; 
John Wiley, c1998. 
139. Weltzin, M.M. and M.K. Schulte, Desformylflustrabromine Modulates 
alpha4beta2 Neuronal Nicotinic Acetylcholine Receptor High- and Low-
Sensitivity Isoforms at Allosteric Clefts Containing the beta2 Subunit. J 
Pharmacol Exp Ther, 2015. 354(2): p. 184-94. 
140. González-Rubio, J.M., et al., Choline as a tool to evaluate nicotinic receptor 
function in chromaffin cells. Cell Biology of the Chromaffin Cell, 2004. 
  
87 
 
141. Coiquhoun, L.M. and J.W. Patrick, α3, β2, and β4 Form Heterotrimeric 
Neuronal Nicotinic Acetylcholine Receptors in Xenopus Oocytes. Journal of 
Neurochemistry, 1997. 69: p. 2355-2362. 
142. Parker, M.J., A. Beck, and C.W. Luetje, Neuronal Nicotinic Receptor β2 and 
β4 subunits confer large differences in agonist binding affinity. Molecular 
Pharmacology, 1998. 54: p. 1132-1139. 
143. Scremin, O.U. and D.J. Jenden, Time-dependent changes in cerebral choline 
and acetylcholine induced by transient global ischemia in rats. Stroke, 1991. 
22(5): p. 643-7. 
144. Gotti, C., et al., Structural and functional diversity of native brain neuronal 
nicotinic receptors. Biochem Pharmacol, 2009. 78(7): p. 703-11. 
 
 
 
 
 
 
 
